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Abstract 
 
Vascular growth disorders are the major contributing factor to cardiovascular 
disease, the leading cause of morbidity and mortality worldwide.  Aberrant vascular 
smooth muscle cell (VSMC) growth is a primary etiology foundational to the 
pathophysiology of this disorder.  Recent findings support growth control of VSM by the 
metabolic sensor adenosine monophosphate-activated protein kinase (AMPK).  
Therefore, the aim of this project was to test our hypothesis that AMPK has ability to 
inhibit VSM growth in vivo by reducing neointima formation in rat carotid arteries 
following injury and in vitro by promoting VSMC cytostasis in rat thoracic aorta VSMCs.  
Our data reveal that local or systemic pre-treatment with the AMPK agonist AICAR 
significantly increases VSM AMPK activity and inhibits neointima formation in rat 
carotids following balloon injury.  In cultured VSMCs AICAR also induced AMPK 
signaling and elicited cytostatic growth arrest via protein phosphatase 2A and cyclin-
dependent kinase (CDK) inhibitor p21-mediated reduction of G0/G1 and S-phase cell 
cycling.   Additionally, data reveal that phosphorylation of microfilament-associated 
vasodilator-activated serum phosphoprotein (VASP) by AMPK reduces pro-migratory 
events including microfilament elongation, actin strain-induced autophosphorylation of 
focal adhesion kinase (FAK), and focal adhesion turnover.  Furthermore, AMPK 
reduced extracellular matrix proteolysis by matrix metalloproteinase (MMP)-9.  Finally, 
evidence is provided for a positive signaling nexus between AMPK and cyclic adenosine 
monophosphate (cAMP)-dependent protein kinase (PKA) whereby these two systems 
cooperatively enhance the cytostatic actions of AMPK.  Altogether, these results provide 
compelling evidence that AMPK regulates cytoskeletal/focal adhesion dynamics and cell 
cycle progression in an effort to reduce VSM growth in both in vitro and in vivo settings.  
These data increase our understanding of the role of this important metabolic regulator 
within VSMCs and provide support for its continued investigation in the metabolically-
directed treatment of vasculoproliferative disorders.   
 
 
  
Adenosine Monophosphate-Activated Protein Kinase Inhibits Vascular Smooth 
Muscle Growth Associated With Vasculoproliferative Disorders 
 
 
A Dissertation 
Presented To the Faculty of the Department of Physiology 
East Carolina University 
 
In Partial Fulfillment of the Requirements for the Degree 
Doctorate of Philosophy in Physiology 
 
 
 
by 
Joshua D. Stone 
July, 2013 
 
  
 
 
 
 
 
 
	  
	  
	  
	  
©	  Joshua D. Stone, 2013 
 
Adenosine Monophosphate-Activated Protein Kinase Inhibits Vascular Smooth 
Muscle Growth Associated With Vasculoproliferative Disorders 
by 
Joshua Stone 
 
APPROVED BY: 
DIRECTOR OF DISSERTATION:  ___________________________________________  
 (David Tulis, Ph.D.)  
 
COMMITTEE MEMBER:  _____________________________________________   
 (Stefan Clemens, Ph.D.)  
 
COMMITTEE MEMBER:  _____________________________________________   
 (Christopher Geyer, Ph.D.)  
 
COMMITTEE MEMBER:  _____________________________________________   
 (Darrell Neufer, Ph.D.)  
 
COMMITTEE MEMBER:  _____________________________________________   
 (Carol Witczak, Ph.D.)  
 
COMMITTEE MEMBER:   _____________________________________________ 
       (Michael Van Scott, Ph.D.) 
 
CHAIR OF THE DEPARTMENT  
OF PHYSIOLOGY:   ______________________________________________  
                                                                    (Robert Lust, Ph.D.)  
 
DEAN OF THE  
GRADUATE SCHOOL: ____________________________________________  
          (Paul Gemperline, Ph.D.) 
 
 
Dedication 
 
I dedicate this dissertation to my loving and supportive wife, Missy, and to my 
adorable kids, Alina and Levi.  I love you all more than you could ever know!  Thank you 
for being my biggest fans! 
 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES  ................................................................................................  vi 
CHAPTER 1:  Background and Significance ...........................................................  1 
 Cardiovascular Disease  ...............................................................................  1 
  Vascular Growth Disorders  ...............................................................  1 
 AMP-Activated Protein Kinase....................................................................... 2  
  Overview ............................................................................................  3 
  AMPK and Vascular Growth ..............................................................  4 
CHAPTER 2: Materials and Methods ………………………………………………….  7 
CHAPTER 3:  AMP-Activated Protein Kinase Inhibits Vascular Smooth  
Muscle Cell Proliferation and Migration and Vascular Remodeling Following  
Injury .......................................................................................................................  16 
 Abstract ........................................................................................................  17 
 Introduction ..................................................................................................  18 
 Results........................................................................................................... 20 
 Discussion.....................................................................................................  39 
CHAPTER 4:  Inhibition of Vascular Smooth Muscle Growth via Signaling  
Crosstalk Between AMP-Activated Protein Kinase and cAMP-Dependent Protein  
Kinase …………………………………………………………………………………….   47 
 Abstract ........................................................................................................  48 
 Introduction ..................................................................................................  50 
 Results........................................................................................................... 52 
 
 
 Discussion.....................................................................................................  69 
CHAPTER 5:  AMP-Activated Protein Kinase Inhibits Transforming Growth  
Factor-β-1-Induced Vascular Smooth Muscle Cell Growth  ....................................  77 
 Abstract ........................................................................................................  78 
 Introduction .................................................................................. ................  80 
 Results........................................................................................................... 82 
 Discussion.....................................................................................................  94 
CHAPTER 6:  AMP-Activated Protein Kinase Inhibits Vascular Smooth  
Muscle Cell Growth in a Vasodilator-Activated Serum Phosphoprotein- 
Dependent Manner  ................................................................................................  101 
 Abstract ........................................................................................................  102 
 Introduction .................................................................................. ................  104 
 Results........................................................................................................... 106 
 Discussion.....................................................................................................  118 
CHAPTER 7: Unified Discussion ……………………………………………………….. 124 
 Unified Schematic .......................................................................................... 132 
REFERENCES ……….............................................................................................. 135 
 
 
LIST OF FIGURES 
 
Figure 3.1.	  AICAR or A-769662 activate AMPK in rat carotid arteries ....................  21 
Figure 3.2.	  AMPK inhibits neointima formation 2 weeks after carotid artery      
balloon injury ...........................................................................................................  22 
Figure 3.3.	  AICAR increases AMPK signaling in rat primary VSMCs......................  24 
Figure 3.4.	  AMPK induces cell cycle arrest and inhibits VSMC proliferation  ..........  26 
Figure 3.5.	  AMPK promotes protein phosphatase-2A activity and reduces cell  
cyclin B expression  .................................................................................................  27 
Figure 3.6.	  AMPK inhibits VSMC migration  ............................................................  29 
Figure 3.7.	  AMPK inhibits VASP-mediated actin anti-capping  ...............................  31 
Figure 3.8.	  AMPK promotes actin de-polymerization and stress fiber  
formation  .................................................................................................................  32 
Figure 3.9.	  AMPK inhibits FAK activity  ...................................................................  34 
Figure 3.10.	  AMPK promotes anti-migratory signaling through paxillin  ..................  36 
Figure 3.11.	  AMPK inhibits MMP-9 proteolysis of VSMC extracellular matrix  ........  38 
Figure 3.12.	  Schematic depicting the proposed role of AMPK in the control of  
VSM growth ……………………………………………………………………………….  44 
Figure 4.1.	  AICAR increases AMPK signaling in primary rat VSMCs as  
measured via In-Cell Western Blotting  ...................................................................  53 
Figure 4.2.	  AICAR increases AMPK signaling in rat primary VSMC lysates  ..........  55 
Figure 4.3.	  AMPK enhances PKA activity  ...............................................................  56 
Figure 4.4.	  FSK increases PKA signaling in rat primary VSMCs  ............................  58 
Figure 4.5.	  PKA increases AMPK activity in VSMCs	   ..............................................  60 
 
 
Figure 4.6.	  AICAR increases phosphorylation of AMPK at Ser485 in  
PKA-independent fashion  .......................................................................................  62 
Figure 4.7.	  PKA inhibits global and isoform-specific Ser/Thr phosphatase  
activity  .....................................................................................................................  64 
Figure 4.8.	  AMPK inhibits VSMC migration  ............................................................  66 
Figure 4.9.	  AMPK induces cell cycle arrest and inhibits VSMC proliferation  ..........  68 
Figure 4.10.	  Schematic depicting the proposed cooperative relationship  
between AMPK and PKA in the control of VSM growth  .........................................  74 
Figure 5.1.	  AMPK inhibits TGFβ1 signaling  ............................................................  84 
Figure 5.2.	  AMPK reverses TGFβ1-induced cell cycle progression  .......................  86  
Figure 5.3.	  AMPK reverses TGFβ1-induced cell proliferation  ................................  87 
Figure 5.4.	  AMPK inhibits TGFβ1-induced cyclin expression  .................................  89 
Figure 5.5.	  AMPK inhibits TGFβ1-induced CDK expression  ..................................  91 
Figure 5.6.	  AMPK induces CDK-inhibitor expression  .............................................  93 
Figure 5.7.	  Schematic depicting the proposed inhibitory actions of AMPK on  
TGFβ1-induced VSMC growth  ...............................................................................  98 
Figure 6.1.	  AMPK specifically phosphorylates VASP  .............................................  108 
Figure 6.2.	  AMPK/VASP promotes actin de-polymerization  ...................................  110 
Figure 6.3.	  AMPK/VASP inhibits FAK activation  ....................................................  112 
Figure 6.4.	  AMPK/VASP promotes focal adhesion stability  ....................................  113 
Figure 6.5.	  AMPK/VASP inhibits VSMC migration  .................................................  115 
Figure 6.6.	  AMPK inhibits cell cycle progression in a VASP-dependent  
manner ....................................................................................................................  117 
 
 
Figure 6.7.	  Schematic depicting the proposed functional relationship of  
AMPK and VASP in the inhibition of VSMC growth .................................................  122 
Figure 7.1.  Unified Schematic …………………………………………………….…..  132
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Chapter 1: Background and Significance 
  
Cardiovascular disease (CVD) is the number one cause of fatality worldwide 
and accounts for greater than half of diagnosed noncomunicable diseases (28, 54).  
One in three deaths in America is a result of CVD with nearly 55% of all deaths having 
CV-related etiologies (28).  CVD is a continuum of diseases which involve either the 
heart or the vasculature or both.  The disease etiology is quite diverse; however, 
hypertension and atherosclerosis are the primary causative factors (81).  The primary 
risk factors of CVD, which together promote the progression and complication of the 
disease include obesity, dyslipidemia, diabetes mellitus, metabolic syndrome, chronic 
kidney disease, and smoking (28, 54).   
Although myocardial infarct (MI) and/or heart failure (HF) are primary clinical foci, 
according to the American Heart Association over 50% of CVDs are strictly vascular in 
origin (81).  Vascular disease can be coronary, cerebrovascular, and/or peripheral in 
nature; however, all have the same pathophysiology which includes aberrant vascular 
growth and fibrosis.  Abnormal vascular growth provides the primary mechanism 
underlying numerous vessel pathologies including atherosclerosis, pressure- and/or 
flow-mediated hypertrophy, stent-induced hyperplasia, and iatrogenic restenosis after 
intervention (44, 62, 118).  Un-diagnosed and/or un-treated progression of vascular 
growth within a lipid-rich environment leads to plaque formation and luminal narrowing, 
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vessel stenosis, and ischemia in downstream tissues.  
Aberrant vascular smooth muscle (VSM) growth is a pivotal mechanistic 
underpinning for these pathologies.  While the arterial wall contains a heterogenous 
population of VSM cells (VSMCs) (34, 71, 79), under homeostatic conditions VSMCs 
maintain a cytostatic and contractile phenotype.  The transformation of normally 
quiescent VSMCs to an activated state is initiated by mitogenic factors and/or 
mechanical injury to the vessel.  These transformative events induce inflammation, 
which initiates the transcription and secretion of numerous chemokines thus further 
exacerbating and promoting inflammation,  and VSMC migration, proliferation, and 
secretion of matrix proteins including collagens.  These events lay the foundation for 
deleterious luminal narrowing and vessel stenosis associated with atherosclerosis, 
vessel hypertrophy, and restenosis following injury or clinical intervention (44, 62, 77, 
82).  Despite a plethora of studies aimed at reducing “phenotypic switching” of activated 
VSMCs, abnormal VSM growth remains a critical contributor to vascular 
pathophysiology with no absolute clinically-effective treatment identified to date.  
Therefore, given the current clinical and economic burden of vascular diseases, 
advanced therapeutic approaches to curb vascular growth are much needed.  
 
AMPK:  Adenosine monophosphate-activated protein kinase is a ubiquitously 
expressed heterotrimeric Serine (Ser)/Threonine (Thr) kinase consisting of a catalytic α-
subunit and two regulatory subunits β and γ (36, 66, 84, 87).  The kinase responds to a 
rise in the AMP:ATP ratio under metabolic challenge as well as to chemical and 
physical stresses.  AMP binding is suggested to aid in partial activation of the kinase 
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causing a conformational change of the protein revealing the activation site for 
phosphorylation as well as providing significant protection from protein phosphatase 
deactivation (87).  For full catalytic activity of the kinase, upstream phosphorylation of 
αT172 is required (84, 87).  The tumor suppressor protein LKB1 was first described as 
the AMPK kinase (AMPKK); however, other AMPKKs have recently been described 
including calcium-dependent CaMKK and the TGFβ activated kinase TAK1.  AMPK can 
also be activated hormonally by leptin or adiponectin (36, 66, 84, 87).  Alternate alpha 
moieties, such as Ser 173 (19) or 485 (42), have been suggested to serve inhibitory 
functions on AMPK activity; however, these findings are tissue-dependent and their 
specific function remains unclear. 
 
Actions of AMPK:  Upon activation of AMPK, energy producing pathways are 
upregulated while energy consuming pathways are shut off or rendered minimally active 
(36, 66, 84, 87).  AMPK also phosphorylates and inhibits many key metabolic enzymes 
such as glycogen synthase, HMG-CoA reductase, and acetyl CoA carboxylase (36, 84, 
87).  In a traditional sense AMPK responds to stimuli by inhibiting ATP-depleting 
processes such as cholesterol and protein synthesis while promoting carbohydrate and 
lipid metabolism, thus increasing ATP synthesis and restoring energy homeostasis 
within the cell (84, 87). However, more recent studies suggest that AMPK offers 
significant cardio- and vascular-protective roles by inhibiting cardiac and smooth muscle 
reactive oxygen species (ROS), reducing fibrosis, and enhancing vascular relaxation by 
increasing endothelial nitric oxide synthase (eNOS) activity and NO production	  (23, 83). 
Moreover, recent reports suggest that AMPK plays a significant role in cellular growth 
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arrest (23, 35, 61, 64, 99), making it an ideal candidate for studies targeted at reducing 
uncontrolled VSM growth.   
  
AMPK and Vascular Growth: In intact blood vessels the progression of growth 
disorders culminates from the activation of VSMCs within the medial wall.  This 
phenotypic activation of VSMCs promotes their enluminal migration, proliferation, and 
matrix deposition with ensuing neointimal development. Given the ability of AMPK to 
regulate synthetic processes within the cell, it is logical to think that AMPK could 
regulate specific energy consuming pathways within VSMCs that promote cell migration 
and proliferation. 
Recent reports suggest that AMPK plays a significant role in cellular growth arrest 
(23, 35, 61, 64, 99).  In particular, AMPK has been implicated in the inhibition of G0/G1 
cell cycle progression and cytostasis in commercial human VSMCs (43).  It is suggested 
that AMPK can inhibit neointima formation in rat femoral arteries following injury (67).  A 
recent comprehensive study in mouse femoral arteries (97) proposed that AMPKα2 is 
the predominant isoform responsible for these growth inhibitory responses.  However, 
since AMPK possesses two catalytic isoforms, α1 and α2, and AMPKα1 is the 
predominant isoform in VSM (84), the exact role of the two isoforms under physiologic 
and stimulated conditions remains unclear.  Additionally, we recently reported that 
AMPK has capacity to communicate with protein kinase A in growth inhibition of primary 
VSMCs (99).  
The physical migration of cells along a substrate is dependent upon highly dynamic 
actin cytoskeletal and focal adhesion regulation (4, 89).  It has been reported that AMPK 
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has the capacity to phosphorylate and de-activate actin-associated vasodilator-activated 
serum phosphoprotein (VASP) (9) and to increase focal adhesion integrity and actin 
bundling (65).  Together, by inhibiting the microfilament assembly necessary to promote 
cell extension and increasing the anchoring of a cell to its substrate, these data 
represent a potential mechanism by which AMPK could inhibit VSMC migration.  It is 
noteworthy that many potential mechanisms of AMPK-mediated anti-migration may 
exist; however, this area of investigation within VSMCs and vascular growth remains 
fairly unexplored.  Therefore, our initial investigations focused on the role of AMPK in 
regulating the actin cytoskeleton and focal adhesion contacts. 
 While these early findings lend support for anti-growth properties of AMPK within the 
vasculature, the specific mechanisms involved particularly related to proliferation and 
migration remains elusive; however, these justify further investigation into AMPK as a 
potential therapeutic target for use in reducing VSM growth disorders.  Given the 
cytostatic (anti-proliferative and anti-migratory) capacities of AMPK, it makes sense that 
AMPK may play a major role in the reduction of VSM growth.  Of these, specific 
mechanisms employed by AMPK to inhibit VSMC cell cycling and chemotaxis  are 
especially intriguing yet are largely unexplored and possess critical basic science and 
clinical importance.   
Data presented here lend support for our hypothesis that AMPK inhibits vascular 
remodeling by inhibiting cell migration in an actin cytoskeleton-associated fashion, and 
cell growth in a cell cycle regulatory fashion.  Here we propose mechanisms employed 
by AMPK in an effort to reduce VSMC growth and that induction of these signaling 
events effectively reduce the intimal remodeling of rat carotid arteries following balloon 
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injury.  In brief, our findings show that AMPK significantly reduces neointimal 
development through cytostatic inhibition of VSMC proliferation and migration.  
Mechanistic data support roles for AMPK in the stabilization of the actin cytoskeleton 
and in the enhancement of focal adhesion and ECM stability.  Additionally, we provide 
data suggesting AMPK inhibits VSMC proliferation through cell cycle inhibition.  
Moreover, we provide early data that suggest both the anti-proliferative and anti-
migratory actions of AMPK operate through inhibition of VASP.  These findings provide 
strong evidence for AMPK as a physiological regulator of VSM growth and offer support 
for its continued study. 
 
	  
 
 
Chapter 2: Materials and Methods 
 
This investigation was approved by the East Carolina University Animal Care and 
Use Committee and conformed to the Guide for the Care and Use of Laboratory 
Animals (U.S. National Institutes of Health, Publication No. 85-23, revised 1996). 
 
Materials 
AICAR was purchased from Toronto Research Company (North York, Ontario) and 
Invitrogen (Carlsbad, California), Compound C was purchased from Invitrogen, A-
769662 was purchased from Tocris (Minneapolis, MN), forskolin and PKI were 
purchased from Enzo Life Sciences (Farmingdale, New York), and IBMX was 
purchased from Calbiochem (Darmstadt, Germany).  Recombinant TGFβ1 was 
purchased from R&D Systems (Minneapolis, Minnesota).  All primary antibodies were 
purchased from Abcam (Cambridge, Massachusetts), ECM Biosciences (Versailles, 
Kentucky), or Cell Signaling (Danvers, Massachusetts), were diluted 1:1000 for In-Cell 
and chemiluminscent Western blotting, or 1:500 for immunofluorescence detected by 
flow cytometry and were targeted against the following:  AMPK, pAMPKThr172, 
pAMPKSer485; ACC, pACCSer80; PKA, pPKAThr197; VASP, pVASPSer157, pVASPThr278; FAK, 
pFAKTyr397, paxillin; Smad2, pSmad2Thr8, Smad3, pSmad3Ser423, Smad7; cyclin D, cyclin 
E, CDK2, CDK4, CDK6, p21, p27; α-tubulin, and β-actin.  Antibodies were diluted in 
IRDye blocking buffer (Rockland; Gilbertsville, Pennsylvania) for In-Cell Western 
blotting or 1% bovine serum albumen (BSA) in PBS (Gemini; Stoneham, MA) for 
immunofluorescence.    IRDye secondary antibodies (1:1000; Rockland) and FITC- or 
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TxRed-conjugated secondary antibodies (1:10000; Rockland) were used for protein 
detection while Draq 5 (1:10000; Cell Signaling) and Sapphire 700 (1:1000; Li-Cor; 
Lincoln, Nebraska) were used for DNA staining and protein normalization.  Propidium 
iodide (PI) and RNAse for cell cycle analysis were purchased from Invitrogen.  
AlexaFluor-conjugated deoxyribonuclease I or phalloidin stains for G-actin and F-actin 
were purchased from Invitrogen. 
 
Methods  
Rat carotid artery balloon injury 
Experimental balloon injury was performed on the left carotid artery of male 
Sprague Dawley rats (500 g) as we have previously described (109, 111).  Briefly, 
animals were anesthetized (ketamine (90 mg/ml)/xylazine (10 mg/ml); 1.0 mL/kg body 
weight, intraperitoneal) and a Fogarty 2F embolectomy catheter (Edwards Lifesciences 
Corporation, Irvine, CA) was introduced through an arteriotomy site and advanced 
through the left carotid artery (LCA), inflated, and withdrawn with rotation three times to 
achieve arterial injury.  The exposed portion of the LCA was treated with either 0.5 
mg/kg bw AICAR or A769662 in 1 mL pluronic gel or equal amounts vehicle in pluronic 
gel and the tissues were closed and the animals given meloxicam (1 mL/kg, 
subcutaneous) for pain.   
 
Tissue Processing and Staining 
Two weeks following surgery animals were anesthetized and euthanized by 
pneumothorax and exsanguination.  Tissues were perfusion-fixed, paraffin-embedded, 
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and standard staining techniques were utilized to analyze vessel growth as we have 
previously described (109).  Briefly, neointimal (NI) and medial wall (MW) areas were 
measured and their ratios were calculated (as NI/MW) as a standard measure of 
remodeling (109).  Also, perimeters of the internal and external elastic laminae were 
measured to obtain vessel circumferences (56).  Additionally, a small cohort of animals 
was euthanized at varying times, and carotids were excised and homogenized for 
protein analysis as described (112). 
 
Cell culture 
Primary VSMCs were isolated from thoracic aortae of male Sprague-Dawley rats 
(100-125 grams; Charles River Labs) by collagenase and elastase digestion and 
characterized morphologically as previously described (20).  VSMCs were cultured in 
Dulbecco's Modified Eagles Medium (DMEM) supplemented with Fetal Bovine Serum 
(FBS, 0.5-10%), 2 mM L-glutamine, and 1:500 dilution of 50 ug/mL Primocin at 37 °C in 
95% air/5% CO2.  Cells were serially split and used through passage 6 (12, 47,	  99).  For 
all assays, n is calculated as at least 3 separate trials each with at least 3 wells (or 
reads) per assay from serially-split clonal cells. 
 
Protein detection  
VSMCs were seeded in 96-well plates and, once confluent, were treated with 
specified agents.  After treatment, cells were formalin-fixed and protein phosphorylation 
was determined by In-Cell Western analysis as recently described (1, 48, 99).  Briefly, 
fixed cells were permeabilized with 0.1% Triton-X, blocked with IRDye blocking buffer 
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and treated with rabbit anti-rat primary antibodies (1 h; RT).  Target proteins were IR-
labeled and DNA was stained for protein normalization.   Fluorescence was detected 
and analyzed using Li-Cor Odyssey Infrared Imaging System and software.  Traditional 
Western blots were performed on primary cell lysates as previously described (49, 63, 
113) in order to confirm AMPK activation and to complement In-Cell Western data.  
 
Assessment of Kinase activity 
 VSMCs were seeded in 96-well plates and, once confluent, were treated with specified 
pharmacologic agents.  After treatment, cells were formalin-fixed, and protein 
phosphorylation was determined by In-Cell Western analysis as recently described (2, 
47).  Briefly, fixed cells were permeabilized with 0.1% Triton-X, blocked with IRDye 
blocking buffer and treated with rabbit anti-rat primary antibodies for 1 hour at RT.  
Target proteins were IR-labeled and DNA was stained for protein normalization.  
Fluorescence was detected and analyzed using Li-Cor Odyssey Infrared Imaging 
System and software.  Additionally, traditional Western blots were performed on primary 
cell lysates as previously described (63, 113) to verify In-Cell Western data for select 
experiments.  For specific activity, treated cells were lysed in buffer (50mM Tris, pH 6.8; 
1% SDS; 0.1% Triton; protease inhibitor cocktail (Thermo); phosphate inhibitor cocktail 
(Thermo)), and added to wells of a 96-well microtiter plate.  ELISA-based activity 
assays were performed per manufacturer’s instructions.  Briefly, for AMPK (MBL 
International, Woburn, Massachusetts), activity was assessed using a mouse insulin 
receptor substrate phospho-serine 789 reporter with HRP chemiluminescence at 450nm 
(58, 106).  For PKA (Enzo Life Sciences), activity was measured by 
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tetramethylbenzidine substrate color development proportional to PKA 
phosphotransferase activity and measured at 450 nm as described (13).   
 
Phosphatase Activity 
 Cells were harvested in phosphatase inhibitor-free buffer, prepared according to 
manufacturer’s suggestion (Invitrogen), and added to wells of microtiter plates 
containing 6,8-difluoro-4methyl-umbelliferyl phosphate substrate.  When activated by 
phosphatases, DiFMU was generated in proportion to phosphatase activity, which was 
read at 450 nm.  For specific (PP-2A and PP-2C) phosphatase activities, additional 
components were added to the buffer per manufacturer’s directions that allowed for 
activity analyses of specific phosphatases within the lysate (50, 72). 
 
MMP activity analysis 
MMP activity was assessed by matrix gel zymography (55).  Briefly, conditioned 
media was electrophoresed in a 10% zymogram gel containing 1mg/mL gelatin.  The 
gel then underwent a series of washings at RT for 2 hrs followed by an overnight 
incubation at 37°C in renaturing buffer.  The gel was then stained with Coomassie blue 
and visualized using an Epson Perfection V750 Pro scanner.  Proteolytic activity was 
assessed as the density of a white band (indicative of enzymatic digestion) on a dark 
blue field.  Additionally, expression of tissue inhibitor of MMP (TIMP) was analyzed from 
the conditioned media of treated cells by traditional Western blot as we have described 
previously (63, 113). 
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Immunocytochemistry:   
VSMCs were seeded on glass coverslips and allowed to adhere.  Cells were treated 
for 1-48 hrs with select pharmacologic agents, formalin-fixed, permeabilized (0.1% 
Triton-X), and blocked with 3% BSA in PBS + 0.1% Tween-20 (PBST).  Protein IgG 
reactions were carried out using selective primary antibodies followed by 
counterstaining with fluorescently-tagged secondary antibodies (FITC and TxRed). 
Fluorescently-tagged phalloidin and deoxyribonuclease I were used to detect F- and G-
actin, respectively.  
 
Immunofluorescence:  
Confluent VSMCs were treated with select pharmacologic agents for 1-24 hours 
then trypsinized, fixed with 4% formalin, washed with PBS, permeabilized with 0.1% 
Triton-X in PBS, washed, and blocked with 1% BSA in PBS.  Select proteins were 
detected by primary/secondary conjugation in 1% BSA and analyzed by flow cytometry.  
Fluorescently-tagged phalloidin and deoxyribonuclease I were used to detect F- and G-
actin, respectively analyzed by flow cytometry (Accuri C6 Flow Cytometer) using CFlow 
Plus software (Accuri) (100). 
 
Cell cycle analysis 
Cells were plated in 12-well plates at 80,000 cells/well in complete media until ~50% 
confluent.  Cells were quiesced in 0.5% FBS for 24 hours followed by treatment in 
complete growth media (DMEM, 10% FBS, Primocin) containing select pharmacologic 
agents for 24 hours.  Cells were trypsinized and stained with propidium iodide (PI; 
 
	   	   	    13	  
Invitrogen) per manufacturer’s recommendations (47, 99).  The fraction of cells present 
in each phase of the cell cycle was assessed by flow cytometry (C6, Accuri). 
 
Cell proliferation and viability analyses 
VSMCs were plated in 6-well plates at 180,000 cells/well in complete media until 
~50% confluent.  Cells were quiesced in 0.5% FBS for 24 hours followed by treatment in 
complete growth media for 48 hours as described.  Cells were trypsinized and 
proliferation and viability were assessed through automated cell counting with trypan 
blue exclusion staining (ViCell, Beckman Coulter). 
 
Cell migration analyses 
Following protocols previously described with minor modifications (47, 59), VSMCs 
were seeded at 180,000 cells/ml in the upper chamber of a Fluorblok transwell system 
(BD) in complete media and allowed to adhere.  Cells were then treated for 1 hour 
following staining with Cell Tracker Green (10 uM; Invitrogen).  Serum-free media was 
applied to the upper chamber containing the same original treatment and 10 ng PDGFβ 
was applied to the bottom chamber as a chemoattractant (124).  Cell migration was 
assessed from time 0 through 18 hours by bottom-read fluorescence at 525 nm (Tecan 
Infinite M200) with each time point random fluorescent units (RFU) normalized to time=0 
RFU for each respective condition.  Net migration was calculated as a fold change of 
the total migration for each condition over total control (vehicle) migration at 18 hours. 
Additionally, using a wounding assay cells were grown to confluence in 6-well plates 
and select pharmacologic agents were added to the growth media for 1 hour.  Following 
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treatment cells were wounded with a 2mm blade and the rate of wound healing was 
assessed by photomicrography through 24 hours. 
 
Anti-VASP Lv-shRNA transduction  
Lv-shRNA (SMART vector 2.0) directed against the full length VASP or non-
targeting controls (NTC; Dharmacon Research, Lafayette, CO) were utilized to reduce 
expression of endogenous VASP.  Transduction efficiencies and appropriate multiplicity 
of infection (MOI) were determined per manufacturer’s guidelines.  Rat VSMCs were 
plated in 96-well plates at 40% confluence and switched to 0.5% serum following 
adherence.  Cells were treated with Lv-shRNA SMART vector 2.0 against full length 
VASP (MOI 0.3-5) or NTC controls for 24 hours in transduction media lacking antibiotic.  
Media was changed after 24 hours to high glucose-DMEM, 15% FBS and 
penicillin/streptomycin mix, and on day 3 cells were expanded to 24-well plates and 
VASP mutants were selected by Puromycin resistance for 24 hours.  Stable cell lines 
were established and used as needed for verification of VASP deficiency and cell 
growth assays.    
 
Statistical analyses 
Data were analyzed using Excel 2011 (Microsoft) and Sigma Plot 11.2 (SPSS, Inc.).  
All data sets were tested for normal distribution and met the homogeneity prerequisites 
for analysis of variance (ANOVA).  One-way ANOVA and Tukey’s post-hoc multiple 
comparison tests were used to detect changes between individual groups.  Two-way 
ANOVA with multiple comparisons and Tukey’s post-hoc tests were used for protein 
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phosphatase analysis, migration, and cell cycle analysis to detect significance among 
groups.  Data are expressed as mean ± standard error of the mean (SEM), with a p < 
0.05 considered statistically significant.	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Abstract 
 
Vascular smooth muscle cell (VSMC) activation promotes a synthetic phenotype that 
underlies many vessel growth disorders.  In this regard it has been suggested that the 
metabolic sensor adenosine monophosphate-activated protein kinase (AMPK) has 
significant anti-growth and anti-metastatic properties and may serve as a viable 
therapeutic target.  In the current study we hypothesized that AMPK reduces neointima 
formation following balloon injury and that this occurs through reduction in VSMC 
proliferation and migration.  Data reveal that local or systemic dosing with the AMPK 
agonist AICAR significantly increased AMPK activity in vivo and inhibited neointima 
formation in rat carotid arteries 2 weeks after injury.  In rat primary VSMCs AICAR 
inhibited migration and induced cytostatic growth arrest through increased protein 
phosphatase 2A-mediated inhibition of mitosis-promoting cyclin B.  AICAR also 
significantly enhanced AMPK-specific Thr278 phosphorylation of the actin anti-capping 
vasodilator-activated serum phosphoprotein (VASP), increased G:F actin ratios and 
stress fiber formation, and abrogated PDGF-stimulated Ser397 autophosphorylation of 
focal adhesion kinase, pro-migratory cytoplasmic accumulation of paxillin, and 
extracellular matrix proteolysis by MMP-9.  Together, these results provide compelling 
evidence that AMPK serves to inhibit VSM migration and proliferation through regulation 
of cytoskeletal/focal adhesion/ECM stability, increasing our knowledge of this important 
metabolic regulator and providing support for its continued investigation in the treatment 
of vascular growth disorders.   
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Introduction 
 
Abnormal vascular smooth muscle (VSM) growth is a key mechanistic underpinning 
for many vasculopathies including atherosclerosis, vessel hypertrophy, and restenosis 
following injury or clinical intervention (44, 62, 77).  In intact blood vessels the 
progression of growth disorders culminates from the activation of VSMCs within the 
medial wall, thus promoting their luminal migration, proliferation, and matrix deposition 
and ensuing neointimal development.  The physical migration of cells along a substrate 
is dependent upon highly dynamic actin cytoskeletal and focal adhesion turnover (4, 
89).  Adenosine monophosphate-activated protein kinase (AMPK) is a key metabolic 
sensor that responds to cellular energy deprivation and/or chemical and physical 
stresses.  It has been reported that AMPK has capacity to phosphorylate and de-
activate actin-associated vasodilator-activated serum phosphoprotein (VASP) (9) and to 
increase focal adhesion integrity and actin bundling (65).  Therefore, given the anti-
growth and potential anti-migratory capacities of AMPK, it makes sense that AMPK may 
play major roles in the reduction of VSM growth.  This warrants further investigation in 
order to gain insights into the mechanisms employed by AMPK to control VSM growth.    
The purpose of this study therefore was to examine our hypothesis that AMPK 
inhibits VSM growth by inhibiting cellular migration and cell cycle progression and actin 
cytoskeletal and focal adhesion dynamics.  We propose that these mechanisms are 
employed by AMPK in an effort to reduce VSM growth and that induction of these 
signaling events will effectively reduce neointima formation of rat carotid arteries 
following balloon injury.  In summary, novel findings show that AMPK significantly 
reduces neointimal development through cytostatic inhibition of VSMC proliferation and 
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reduction in migration.  Mechanistic data support roles for AMPK in the stabilization of 
the actin cytoskeleton and in the enhancement of focal adhesion and ECM stability.  
These findings provide strong evidence for AMPK as a physiological regulator of VSM 
growth and offer support for its continued study. 
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Results 
 
Systemic and local AICAR inhibit vascular remodeling 
Previous work by our lab established both systemic pre-treatment (114) and 
localized dosing (115, 116) of pharmacologic agents concomitant with the rat carotid 
artery model of vascular injury (109, 113-115).  In similar fashion, in the current study 
we assessed the effects of systemic pre-treatment as well as localized delivery of the 
well-characterized AMP-mimetic AICAR (14, 67, 99, 103, 121) (0.5 g/kg BW systemic; 1 
mg local) on vascular remodeling in rat balloon-injured carotid arteries.  Additionally, we 
utilized the direct, non-metabolic AMPK-activating small molecule A-769662 (30, 37, 73, 
92) (1 mg) with localized delivery to verify specificity of AICAR-mediated AMPK effects.  
First, in order to verify these treatment regimens on uninjured vessels, daily 
intraperitoneal dosing with AICAR for 2 days or localized perivascular delivery of AICAR 
or A-769662 each significantly induced AMPK activity assessed by Thr172 
phosphorylation (17) in carotid artery lysates compared to vehicle (NaCl or DMSO)-
treated control vessels (Fig. 3.1).   
 
 
 
 
 
 
 
Figure 3.1 
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Figure 3.1.  AICAR or A-769662 activates AMPK in rat carotid arteries.  Male Sprague Dawley rats 
were treated with AICAR either systemically (0.5 g/kg BW intraperitoneal injection, 1x/day for 2 days) or 
locally (1 mg in Pluronic gel) on uninjured left carotid arteries for 24 hours.  Carotid arteries were 
harvested and tissues homogenized and probed for pAMPK-Thr 172 and total AMPK.  In both treatment 
regimens AICAR significantly induced AMPK activity as assessed by Thr172 phosphorylation (A and B).  
Additionally, localized treatment with the small molecule A-769662 significantly increased pAMPK Thr172 
(C).  Data are presented as mean pAMPK-Thr172/total AMPK (+/- SEM) as a marker of AMPK activity 
over 3 separate experiments.  P values less than 0.05 were considered statistically significant.  *= p<0.05 
compared to vehicle (Veh) control; ** = p<0.005 compared to Veh. 
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Two weeks after balloon injury both AICAR and A-769662 significantly reduced 
neointima formation compared to vehicle-treated controls using both systemic (Figs. 
3.2A, 3.2D) and localized (Figs. 3.2B, 3.2C, 3.2E, 3.2F) dosing regimens.  Notably, 
comparable levels of growth inhibition were observed between localized AICAR and A-
769662.  Vessel circumferences, measured as internal and external elastic lamina 
lengths, were obtained to rule out anatomical vessel distension as contributor of the 
observed remodeling but were found not to be significantly different in any treatment 
group compared to vehicle controls (data not shown). 
 
Figure 3.2 
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Figure 3.2.  AMPK inhibits neointima formation 2 weeks after carotid artery balloon injury.  Rats 
were given systemic AICAR (0.5 g/kg BW IP) every 24 hours for 2 days prior to injury, or LCAs were 
given local AICAR (1 mg) or A-769662 (1 mg) in Pluronic gel immediately following injury.  After 14 days 
rats were euthanized and carotids were perfusion-fixed, collected and processed for staining.  (A) 
Representative photomicrographs of balloon-injured, perfusion-fixed Verhoeff-Van Gieson-stained left 
carotid arteries of systemically dosed rats 14 days post-injury. (B and C) Representative 
photomicrographs of carotid arteries as with (A), but using localized delivery of AICAR (B) or A-769662 
(C) on the injured vessel.  (D - F) Neointimal area/medial area for vehicle-, AICAR-, or A-7679662-treated 
carotid arteries 14 days following injury.  Both systemic (D) and local (E) AICAR and local A-769662 (F) 
significantly reduced neointimal growth compared to vehicle-treated vessels.  Data are presented as 
mean +/- SEM for 6-8 separate experiments per cohort.  P values less than 0.05 were considered 
statistically significant.  ** = p<0.005 compared to Vehicle; *** = p<0.001 compared to Vehicle. 
 
AICAR increases AMPK activity in primary VSMCs 
In rat primary VSMCs AICAR (1 mM) significantly enhanced Thr172 phosphorylation 
of AMPK at 1 hour (14, 29, 99, 121) which continued through 24 hours (Fig. 3.3A).  This 
activating phosphorylation was completely reversed by the AMPK inhibitor Compound C 
(CC, 10 uM) at both time points (14, 97, 99, 103), yet CC alone did not alter basal 
(untreated) Thr172 phosphorylation levels.  In addition, an AMPK-specific activity assay 
verified that the observed increases in Thr172 phosphorylation correlate with increased 
activity at both 1 and 24 hours (Fig. 3.3B).  Again, CC alone had no impact on basal 
AMPK activity. 
 
 
Figure 3.3 
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Figure 3.3.  AICAR increases AMPK signaling in rat primary VSMCs.  Cells were treated with AICAR 
(1 mM, 60 min) and/or the AMPK inhibitor Compound C (CC; 10 uM, 60 min) and AMPK-Thr172 
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phosphorylation (A) and AMPK activity (B) were measured respectively by In-Cell Western analysis and 
an AMPK-specific activity assay.  AICAR significantly increased phosphorylation of both AMPK-Thr172 
(A) and AMPK activity (B) after 1 hour and 24 hours, both fully reversible by CC.  CC alone exerted no 
effect on basal AMPK-Thr172 phosphorylation or AMPK activity.  Data are presented at pAMPK-Thr 
172/total AMPK and normalized to DNA content (Draq 5/Sapphire 7) or absorbance at 540 nm for activity, 
and within each study n = 5-7.  P values less than 0.05 were considered statistically significant.  ** = 
p<0.005 compared to control; *** = p<0.001 compared to control; # = p<0.05 compared to respective 
activator treatment. 
 
AMPK inhibits VSMC proliferation 
In rat primary VSMCs AICAR (1 mM) significantly inhibited viable cell numbers after 
48 hours, and CC largely reversed this anti-proliferative effect (Fig. 3.4A).  Interestingly, 
CC alone significantly reduced cell numbers compared with vehicle controls.  Notably, 
using trypan blue exclusion changes in cell viability were not observed in any treatment 
group and overall viability ranged between 85% and 90% after 24 hours (data not 
shown).  Using flow cytometry, AICAR significantly reduced G2/M cell populations and 
significantly increased S phase cell populations after 24 hours compared to vehicle-
treated cells, and the changes in the S and G2/M phases were fully reversed with 
concomitant CC (Fig. 3.4B).  AICAR also induced a non-significant increase in G0/G1 
cell populations which correspond well with the decrease in G2/M cell populations.  
Interestingly, CC alone significantly reduced cell numbers after 48 hours and non-
significantly reduced cells in G2/M after 24 hours. 
 
Figure 3.4 
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Figure 3.4.  AMPK induces cell cycle arrest and inhibits VSMC proliferation.  Cells were treated with 
AICAR (1 mM) and/or Compound C (CC; 10 uM) following overnight quiescence in 0.5% serum.  (A) Cell 
numbers were quantified after 48 hours by automated cell counting and trypan blue exclusion and (B) cell 
cycle progression after 24 hours was analyzed by flow cytometry using propidium iodide.  AICAR 
significantly reduced cell numbers and inhibited cell cycle progression revealed by increased G0/G1 and S 
and reduced G2/M cell numbers.  Of note, CC alone significantly reduced cell numbers compared with 
vehicle controls (A) and significantly reduced cell numbers in G2/M.  Trypan blue exclusion failed to detect 
any differences in cell viability in any treatment group (data not shown).  P values less than 0.05 were 
considered statistically significant after multiple comparisons and two-way ANOVA.  ** = p<0.005 
compared to control; *** = p<0.001 compared to control; # = p<0.05 compared to respective activator 
treatment. 
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It has been suggested that protein phosphatase-2A (PP-2A) has ability to inhibit 
G2/M cell cycle progression by inhibiting the cdc/cyclin B complex (45).  In our study 
using a PP-2A-specific activity assay in primary VSMCs, data show that AMPK 
promotes PP-2A activity (1 mM AICAR; 24 hours) in a CC-reversible fashion (Fig. 3.5A).  
Concomitantly cells treated with AICAR over 24 hours showed significant reductions of 
cyclin B in nuclear fractions compared to controls, which was fully reversed by CC (Fig. 
3.5B).   
 
Figure 3.5 
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Figure 3.5.  AMPK promotes protein phosphatase-2A activity and reduces cell cyclin B 
expression.  Cell lysates were prepared from cells treated with AICAR (1 mM) and/or Compound C (CC; 
10 uM) for 24 hours.  Phosphatase activity of diluted (1:10) lysate samples were measured by DiFMUP 
fluorescence at 452 nm after 10 minutes of incubation in the dark.  Activity analysis revealed that AICAR 
induced global Ser/Thr phosphatase activity compared to control (data not shown).  (A) With addition of 
NiCl2 (1 mM) to the reaction buffer, PP-2A-specific activity was measured and results revealed that 
AICAR significantly elevated PP-2A activity which was reversed by CC.  Treated cells underwent 
fractionation so that nuclear lysates could be electrophoresed and probed for cdc2/cyclin B expression.  
(B) Cyclin B expression was significantly decreased in AICAR-treated cells in a CC-reversible fashion 
compared to controls.  Two-way ANOVA with Tukey’s post-hoc testing was used for multiple comparisons 
across time points as well as within each treatment group for phosphatase activity and one-way ANOVA 
detected differences among groups for protein analysis.  P values less than 0.05 across time within each 
group were considered statistically significant. ** = p<0.005 compared to control; # = p<0.05 compared to 
respective activator treatment. 
 
 AMPK inhibits VSMC migration 
Using a transwell chemotaxis assay, AICAR (1 mM) significantly inhibited PDGF-β 
(20 ng/ml)-induced VSMC migration over 18 hours (Fig. 3.6A).  While CC alone exerted 
no effect on basal levels of migration, AICAR-mediated inhibition of migration was 
partially reversed in the presence of CC and, per a 2-way ANOVA, was not statistically 
different from vehicle controls (p=0.412).  In complement, a wound-healing assay on 
serum-stimulated confluent VSMCs showed that AICAR (1 mM) significantly reduced 
migration (as shown by increased wound width) over a 24 hour period (Figs. 3.6B and 
3.6C).   
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Figure 3.6 
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Figure 3.6.  AMPK inhibits VSMC migration.  (A) Cells were labeled with CellTracker Green and treated 
with AICAR (1 mM) and/or Compound C (10 uM), and PDGF-stimulated (10ng/mL) chemotaxis was 
determined using a modified Boyden chamber apparatus and bottom-read fluorescence at 525 nm 
between 0 and 18 hours.  AICAR significantly reduced cell migration, which showed a non-significant 
reversal with simultaneous CC (A).  CC alone failed to alter basal migration compared to controls.  (B) 
Cells were grown to confluence in 6-well plates and treated the same as above.  A 2 mm blade was used 
to injure the cell monolayer and photomicrographs were taken from time 0 through 24 hours.  
Photomicrographs show vehicle- and AICAR-treated cells immediately after scrape injury (time = 0) and 
after 24 hours.  (C) Measurement of the wound width reveals that AMPK significantly inhibits VSMC 
wound healing after 24 hours.  Two-way ANOVA with Tukey’s post-hoc testing was used for multiple 
comparisons across time points as well as within each treatment group.  P values less than 0.05 across 
time within each group were considered statistically significant.  *= p<0.05 compared to control; ** = 
p<0.005 compared to control. 
 
AMPK promotes actin cytoskeleton stability 
Actin-associated VASP acts as an anti-capping protein that promotes actin 
nucleation and filament elongation required for cell migration (6, 7, 15, 90).  Upon site-
specific phosphorylation VASP is rendered inactive and actin filaments are capped and 
polymerization stops, hence phosphorylated VASP can serve as an anti-migratory 
factor.  It has been shown that VASP possesses an AMPK-specific phosphorylation site 
Thr278 (9).  In this study we show that AICAR (1 mM) significantly increases pVASP-
Thr278 compared to vehicle controls after 1 hour, and this was completely reversed with 
CC (10 uM) (Fig. 3.7).   
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Figure 3.7 
 
 
Figure 3.7.  AMPK inhibits VASP-mediated actin anti-capping.  Cells were treated with AICAR (1 mM, 
60 min) and/or Compound C (CC; 10 uM, 60 min), and VASP Thr278 phosphorylation was measured by 
In-Cell Western analysis.  AICAR significantly induced pVASP Thr278, a proposed AMPK-specific site, 
which was fully reversed by CC.  CC alone did not affect basal pVASP Thr278 status.  Data are 
presented at pVASP Thr278/total VASP and normalized to DNA content (Draq 5/Sapphire 7) for 5-7 
experiments.  P values less than 0.05 were considered statistically significant.  *** = p<0.001 compared to 
control; # = p<0.05 compared to respective activator treatment. 
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Of note, CC alone had no effect on VASP-Thr278 phosphorylation.  
Immunofluorescent flow cytometry for G- and F-actin shows that AICAR significantly 
increases the G:F-actin ratio after 1 hour (Fig. 3.8A) which continues through 24 hours 
(Fig. 3.8B).  At both times CC fully reversed basal and AICAR-induced G:F ratios.  In 
support, phalloidin staining for F-actin suggests that AICAR significantly increases 
(~55%; 9 +/- 2 control vs 20 +/- 3 AICAR/field of view) actin bundling and stress fiber 
formation in primary VSMCs compared to vehicle-treated cells which exhibited an 
organized parallel arrangement of actin fibers (Fig. 3.8C).   
 
Figure 3.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   	   	    33	  
Figure 3.8.  AMPK promotes actin de-polymerization and stress fiber formation.  Cells were treated 
with AICAR (1 mM, 60 min) and/or Compound C (CC; 10 uM, 60 min) and fixed and stained for F-actin 
(fluorescently-tagged phalloidin) or G-actin (fluorescently-tagged deoxyribonuclease I), and fluorescence 
was read by flow cytometry or visualized by fluorescence microscopy.  Immunofluorescence reveals that 
AICAR promotes F-actin disassembly revealed by increased G:F actin in a CC-reversible fashion after (A) 
1 hour continuing through (B) 24 hours.  Notably, CC alone significantly reduced basal G:F actin 
compared to vehicle controls at both times.  (C) Cells were counterstained for F-actin (fluorescently-
tagged phalloidin) and visualized using fluorescent microscopy.  Representative photomicrographs reveal 
that AMPK promotes the disassembly of an organized F-actin array seen in vehicle treated cells 
(arrowheads) and promotes actin bundling and stress fiber formation (stars).  P values less than 0.05 
were considered statistically significant.  ** = p<0.005 compared to control; # = p<0.05 compared to 
respective activator treatment. 
 
AMPK promotes focal adhesion stability 
Focal adhesion kinase (FAK) is largely responsible for focal adhesion turnover and 
the promotion of cell detachment and migration along a substratum (53, 89, 107).  In rat 
primary VSMCs, pFAK-Tyr397, a necessary event for kinase catalytic activity (107), was 
significantly elevated with addition of PDGF-β (10 ng/mL) after 1 hour, yet AICAR 
significantly reduced this activated phosphorylation of FAK in the presence of PDGF-β 
to control levels (Fig. 3.9).  
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Figure 3.9 
 
 
Figure 3.9.  AMPK inhibits FAK activity.  Cells were treated with PDGFβ (10ng/mL, 60 min) 
with/without AICAR (1 mM, 60 min), and FAK Tyr397 phosphorylation was measured as an indication of 
kinase activity.  PDGFβ induced significant pFAK Tyr397, which was fully reversed by AICAR.  Data are 
presented at pFAK Tyr397/total FAK and normalized to DNA content (Draq 5/Sapphire 7) for 5-7 separate 
experiments.  P values less than 0.05 were considered statistically significant.  ** = p<0.005 compared to 
control. 
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 Another essential component of a functional focal adhesion is paxillin (65, 107).  
Immunostaining for paxillin on adherent VSMCs shows marked cytoplasmic staining in 
vehicle-treated cells yet significant nuclear staining in AICAR-treated cells after 24 
hours (Fig. 3.10A).  Immunofluorescence detected by flow cytometry revealed that total 
paxillin content was increased after 24 hours compared to controls which was fully 
reversible in the presence of CC (Fig. 3.10B).  Lastly, it has been suggested that paxillin 
is differentially expressed in each cellular compartment which confers a pro- or anti-
migratory signal within the cell (38, 122).  In this manner, quantitative data from 
immunostaining suggest that AICAR promotes nuclear and membranous accumulation 
of paxillin while preventing cytosolic accumulation after 24 hours compared to vehicle 
treated cells (Fig. 3.10C).   
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Figure 3.10 
Figure 3.10.  AMPK promotes anti-migratory signaling through paxillin.  Cells were treated with 
AICAR (1 mM, 60 min), Compound C (CC; 10 uM, 60 min) or a combination of both then either fixed and 
stained for paxillin or fractionated and probed for paxillin within specific cell compartments.  (A) 
Representative immunofluorescent images suggest widely disperse paxillin staining in vehicle cells while 
AICAR promotes paxillin accumulation (arrows) within the nucleus and at focal contacts.  (B)  Protein 
analysis reveals that AMPK promotes paxillin expression after 24 hours (C) and that this expression is 
contained within the nuclear and membranous fractions, indicative of anti-migratory signaling via paxillin.  
P values less than 0.05 were considered statistically significant.  *= p<0.05 compared to control; ** = 
p<0.005 compared to control. 
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AMPK promotes cell/ECM stability 
The extracellular matrix provides a substrate for cellular binding as well as material 
on which to exert forces necessary for movement.  Growth factors and pro-synthetic 
cytokines promote the production and secretion of matrix metalloproteinases (MMPs) 
that degrade the extracellular matrix and thus regulate cell motility (68).  The 
gelatinases MMP-2 and MMP-9 are integral to VSMC migration (11, 46, 68).  In our 
study, MMP-specific column zymography on conditioned media from vehicle- or AICAR-
treated VSMCs after 24 hours revealed that while no differences were observed in 
MMP-2 activity between these cohorts (Fig. 3.11A), AICAR significantly reduced MMP-9 
activity compared to vehicle controls (Fig. 3.11B).  Regarding MMPs, tissue inhibitor of 
metalloproteinase (TIMP)-1 acts as an extracellular regulator capable of tightly 
controlling MMP-9 activity.  In our study TIMP-1 expression approximately doubled (p < 
0.01) in conditioned media from AICAR-treated VSMCs compared to vehicle controls 
after 24 hours (Fig. 3.11D).    
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Figure 3.11 
 
 
 
Figure 3.11.  AMPK inhibits MMP-9 proteolysis of VSMC extracellular matrix.   Cells were treated 
with either AICAR (1 mM) or Compound C (CC; 10 uM) for 24 hours and conditioned media was 
collected.  Positive controls (POS) are shown on the blot for both MMP-2 and MMP-9.  (A) A 
representative column gel zymogram for MMP activity reveals that while no changes were observed for 
MMP-2 in the presence of induced AMPK (B), AMPK selectively inhibits MMP-9 activity in conditioned 
media of AICAR treated cells as compared to controls (C).  Gel zymograms were run on the same gels, 
but images were separated to exclude empty lanes (denoted as dashes in cell lysate columns).  (D) 
Traditional Western blot reveals that AMPK significantly increases expression of the MMP-9 inhibitor 
TIMP-1 in conditioned media of AICAR-treated cells compared to controls after 24 hours. P values less 
than 0.05 were considered statistically significant.  ** = p<0.005 compared to control. 
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Discussion 
 
Findings in this study support our hypothesis that AMPK has capacity to reduce 
arterial remodeling via inhibition of VSMC proliferation and migration.  Data suggest that 
AMPK, stimulated via two distinct pharmacologic approaches, operates by provoking 
cell cycle arrest through a PP-2A/cyclin B mechanism and by preventing 
cytoskeletal/focal adhesion restructuring necessary for VSMC migration.  These findings 
offer unique insight into AMPK signaling as a novel system with significant therapeutic 
potential in the remediation of vascular growth disorders.  Smooth muscle-mediated 
vascular remodeling plays a pivotal role in the onset and complication of 
vasculoproliferative diseases (44, 62, 77); therefore, targeted therapies are of great 
clinical importance.  Data presented here lend strong support for AMPK as a biologically 
active signaling molecule within VSM capable of curbing cell migration and proliferation 
and extracellular matrix turnover, all major players in pathologic vascular remodeling. 
Using the well established balloon injury model to induce VSMC-mediated vessel 
remodeling (109, 114, 116), we illustrate here that both systemic dosing and local 
application of the AMPK agonist AICAR is sufficient at inducing AMPK activity and at 
markedly reducing neointimal formation (Figs. 3.1, 3.2).  The use of AICAR and CC has 
been established in our lab (99) and by others to respectively promote or inhibit AMPK 
activity, and both agents have been utilized in vivo (25, 67) and in vitro (14, 29, 99, 121) 
in VSM.  In an effort to confirm the results observed by treatment with AICAR, we also 
utilized a specific and non-metabolic agonist of AMPK, the small molecule A-769662.  
This agent has been documented to directly activate AMPK in cell-free systems, in 
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intact cells, and in vivo without the side effects associated with the more traditional 
AMPK-activating biguanides (30).  Importantly, A-769662 has been recently 
characterized for use in activating AMPK in vascular cells (73).  Specifically, in our 
current study considering that the rat artery balloon injury model represents an in vivo 
proof-of-concept of our in vitro findings using isolated primary VSM cells, we used A-
769662 in the in vivo model to further validate our findings with AICAR.  The results 
obtained from localized treatment of injured vessels with A-769662 paralleled the results 
obtained with use of AICAR, thus confirming that the in vivo results as well as those 
obtained in vitro could be attributed to AMPK and not off-target drug-specific effects.  
Results using localized, perivascular delivery of AICAR or A-769662 are noteworthy and 
represent the first report demonstrating that local delivery of AMPK agonists 
immediately following intervention are biologically effective.  Often, an a priori treatment 
to reduce vessel remodeling is not possible and systemic therapies can suffer from 
undesired side effects; however, localized delivery of an agent at the time of vascular 
intervention capable of reducing iatrogenic complications offers high clinical translation. 
In order to examine underlying mechanisms of growth suppression by AMPK, in rat 
primary VSMCs following verification of the biologic activity of AICAR (Fig. 3.3) we show 
its ability to significantly reduce cell numbers through inhibition of cell cycle progression 
(Fig. 3.4).  Flow cytometry revealed that AICAR exerts cytostasis in the G0/G1 and S 
phases with concomitant reduction in progression through to the G2/M phase.  Of note, 
no changes in cell viability were observed in any treatment group; therefore, the 
observed changes in cell number are likely due directly to alterations in cell cycle 
progression and not from overt cytotoxicity.  Additionally, a significant reduction in the 
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cell numbers of CC-treated cells after 48 hours was observed and is complemented by 
a non-significant reduction in G2/M cells after 24 hours.  It is possible to explain these 
phenomena by recent findings from collaborating investigators that revealed non-AMPK 
cytostatic effects of CC alone (74).  Also, CC exhibits irreversible inhibitory actions on 
AMPK (33), and without a functional AMPK system it is plausible to speculate that the 
metabolic status of the cell could be compromised in such a way that after 48 hours CC 
may induce cytotoxic effects.  
It was previously suggested that AMPK has ability to promote cytostasis by cyclin-
dependent kinase inhibition via a p53/p21 pathway in a commercialized human VSM 
cell line (43) or through a Skp2/p27Kip1 pathway in AMPK-deficient mouse VSMCs (97).  
While intriguing and relevant to the current study, these previous reports seem 
somewhat contradictory; therefore, in addition to these findings, alternate mechanisms 
by which AMPK inhibits cell cycle progression are plausible.  It has been reported that 
PP-2A has the ability to disrupt the cdc/cyclin B complex and inhibit G2/M progression.  
Since our cell cycle analysis reveals a large increase in S-phase cells, we investigated 
the hypothesis that PP-2A contributes to the mechanism for AMPK inhibition of VSMC 
proliferation.  Data presented here suggest that AMPK induces PP-2A activity (Fig. 
3.5A) and concomitantly reduces cdc2/cyclinB expression after 24 hours (Fig. 3.5B), 
thus supporting the hypothesis that AMPK works, at least in part, through PP-2A/cyclin 
B to induce S-phase cytostasis. 
In addition to proliferation, VSMC migration is pivotal in the pathophysiology of 
vessel remodeling.  In this study we demonstrate that AMPK plays a key role in the 
inhibition of VSMC migration using two distinct experimental approaches, a modified 
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transwell chemotaxis assay and a wounding assay.  The physical movement of cells 
across a substrate is a complex process highly dependent upon the actin cytoskeleton 
and its interface with focal contacts and the extracellular matrix.  We present one of the 
first reports of how AMPK may act to inhibit VSMC migration, which could offer 
significant therapeutic insight for the curbing of disease processes that arise from an 
induction of cell migration.  Novel data presented here reveal possible mechanisms by 
which AMPK inhibits VSMC migration.  Actin polymerization and leading edge formation 
are critical for directional cellular movement; however, AMPK impairs actin 
polymerization, presumably by inhibiting the anti-capping potential of VASP through 
direct, site-specific phosphorylation (9).  Here we observed significant enhancement of 
pVASP at the AMPK-sensitive T278 site by AICAR (Fig. 3.7).  The resulting impairment 
of actin polymerization is evidenced by concomitant accumulation of G-actin in the 
cytosol and increased stress fiber formation in cultured VSMCs (Fig. 3.8).  Thus, these 
data argue convincingly that AMPK hinders cytoskeletal rearrangement necessary for 
VSMC migration as part of its mechanism of growth retardation. 
Unique findings presented here also reveal that AMPK has potential to inhibit focal 
adhesion turnover necessary for the movement of cells across or through substrata.  
We show that AICAR treatment impairs FAK activation by inhibiting Tyr397 
phosphorylation (Fig. 3.9), a necessary event for kinase activity (107).  Upon activation, 
FAK induces paxillin phosphorylation and targets GTPase activity at the focal adhesion 
allowing for focal contact release (107).  Therefore, inhibition of FAK activity offers 
another possible mechanism by which AMPK mediates inhibition of migration.  
Additionally, it has been suggested that paxillin acts as a bi-directional membrane-to-
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nucleus signaling molecule and that differential accumulation of paxillin in distinct 
cellular compartments is indicative of either a pro- or anti-synthetic/migratory event (38, 
122).  Our data reveal that AICAR prevents cytosolic accumulation of paxillin while 
promoting nuclear accumulation and membrane stability (Fig. 3.10).  Taken together, 
these data reveal a novel and intriguing anti-migratory signaling network via AMPK-
mediated inhibition of FAK and FA/paxillin dissociation, thereby reducing pro-migratory 
signals and promoting focal adhesion stability and growth suppression. 
To more comprehensively address the biophysics of migrating and synthetic 
VSMCs, we assessed activity of the extracellular matrix (ECM)-degrading gelatinolytic 
MMPs.  Upon activation, VSMCs produce and secrete MMP-2 and MMP-9 that act to 
degrade the ECM thereby allowing for VSMC expansion/migration and collagen 
deposition (11, 46, 68).  Here we show that AICAR selectively impairs MMP-9 activity 
and enhances inhibitory TIMP-1 expression (Fig. 3.11), which we suggest promote a 
more stable FA via reduced extracellular matrix degradation thus increasing 
FA/substratum connectivity.  Combined, these data suggest a novel role for AMPK in 
the reduction of MMP-9 activity that may play a key role in the inhibition of cellular 
migration via enhanced FA contacts as well as matrix-based morphological changes in 
the vessel wall following injury. Based on our findings, a schematic is shown in Figure 
12 depicting cellular signaling actions of AMPK in VSM.  
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Figure 3.12 
 
Figure 3.12.  Schematic depicting the proposed role of AMPK in the control of VSM growth.  In this 
diagram blunt lines represent proposed inhibitory mechanisms while arrows represent proposed 
stimulatory mechanisms.  Those pathways that were not directly tested in this study but that remain part 
of our overall hypothesis are presented as dashed lines.  Biochemical and functional data described 
herein suggest that AMPK has ability to inhibit VSMC proliferation by inhibiting cell cycle progression, 
possibly by increasing PP-2A within the nucleus.  Additionally we report that AMPK has ability to inhibit 
VSMC migration, presumably via inhibition of VASP anti-capping actions on actin polymerization and 
increasing focal adhesion integrity.  Additionally, AMPK shows ability to inhibit extracellular matrix 
degradation by MMP-9, which we suggest is under control of inhibitory TIMP-1. Taken together, these 
novel data suggest that AMPK employs both intra- and extra-cellular inhibitory signals to effectively 
increase VSMC spatial stability while also inhibiting cell cycle progression in an effort to promote cell 
senescence.    
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It is important to note that over the 2-week timeframe of our studies there were no 
observable side effects of AICAR (following either local or systemic dosing) or local A-
769662, particularly with body weight, fluid and food intake, or activity.  We have 
previously shown that approximately 60% of the initial localized dose following injury is 
released over 24 hours (112).  This is a reasonable estimate for the duration of AICAR 
and A-769662 bioactivity following localized dosing.  Based on previous studies by our 
lab using localized dosing of agonists following balloon injury (47, 113, 114), we utilized 
1 mg AICAR and 1 mg A-769662 in this study.  For systemic dosing of AICAR, previous 
reports (67) were used to determine an optimal dosing strategy that is devoid of 
potential side effects.  
In conclusion, convincing data presented here provide strong evidence that AMPK is 
a desirable anti-growth target in VSM.  Using the AMPK mimetic AICAR or the AMPK-
activating small molecule A-769662, we present in vivo and in vitro data supporting our 
claims that AMPK abrogates neointimal formation and reduces VSMC proliferation and 
migration.  Mechanistically, ample evidence suggests that AMPK acts to promote S-
phase cytostasis and to inhibit cell migration via stabilizing FA contacts and reducing 
extracellular matrix turnover, thereby minimizing cytoskeleton reorganization necessary 
for migration and reducing pro-migratory signals between the membrane and the 
nucleus.  These data paint a comprehensive picture of discrete AMPK-mediated 
cytostatic signaling networks that have significant clinical relevance in efforts to reduce 
vasculoproliferative pathologies. 
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Abstract 
 
Abnormal vascular smooth muscle (VSM) growth is central in the pathophysiology of 
vascular disease yet fully effective therapies to curb this growth are lacking.  Recent 
findings from our lab and others support growth control of VSM by adenosine 
monophosphate (AMP)-based approaches including the metabolic sensor AMP-
activated protein kinase (AMPK) and cAMP-dependent protein kinase (PKA).  Molecular 
crosstalk between AMPK and PKA has been previously suggested, yet the extent to 
which this occurs and its biological significance in VSM remains unclear. Considering 
their common structural AMP backbone and similar biochemical signaling 
characteristics, we hypothesized that crosstalk exists between AMPK and PKA in the 
regulation of VSM growth.  Using rat primary VSM cells, the AMPK agonist AICAR 
significantly increased AMPK activity and phosphorylation of the catalytic Thr172 site on 
AMPK.  Interestingly, AICAR also phosphorylated a suspected PKA-inhibitory Ser485 
site on AMPK, and these cumulative events were reversed by the PKA inhibitor PKI 
suggesting possible PKA-mediated regulation of AMPK.  AICAR also increased PKA 
activity in reversible fashion.  The cAMP stimulator forskolin increased PKA activity and 
completely ameliorated Ser/Thr protein phosphatase-2C activity, suggesting a potential 
mechanism of AMPK modulation by PKA since inhibition of PKA by PKI reduced AMPK 
activity.  Functionally, AMPK inhibited serum-stimulated cell cycle progression and 
cellular proliferation; however, PKA failed to do so.  Moreover, AMPK and PKA 
independently reduced PDGF-β-stimulated VSM cell migration.  Collectively, these 
results show that AMPK is capable of reducing VSM growth in both anti-proliferative and 
anti-migratory fashions.  Furthermore, these data suggest that AMPK may be 
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modulated by PKA and that positive feedback may exist between these two systems.  
These findings reveal a discrete nexus between AMPK and PKA in VSM and provide 
basis for metabolically-directed targets in reducing pathologic VSM growth. 
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Introduction 
 
Cyclic adenosine monophosphate (cAMP) and its canonical downstream kinase 
PKA are critical signaling factors that exert a variety of functional effects in cardiac and 
vascular tissues.  It is reported that Thr197 of the catalytic subunit of PKA is 
phosphorylated in proportion to PKA activity (94, 98) and is a more precise indicator of 
activity than the previously reported Ser338 moiety (96); however, the exact phospho-
specific mechanisms of activation of PKA and their impact on kinase efficacy in VSM 
remain unclear.  
It has been previously suggested that a biochemical relationship may exist between 
AMPK and PKA (19, 42, 52), although the exact nature of this relationship and the 
extent to which they relate in VSM is uncertain.  The cyclic AMP/PKA system, like 
AMPK, has ability to enhance vasodilation (117, 127) and inhibit vessel growth (18, 39).  
Additionally, PKA and AMPK exhibit capacity either discretely or collectively to regulate 
cellular metabolism, and coordination between their pathways has been reported to 
exist either synergistically (16, 21, 80) or antagonistically (19, 119), depending the 
contextual metabolic demands and the tissue type.  Cellular proliferation is normally 
under tight metabolic control, and although little work has been done to elucidate the 
relationship between these two signaling systems in the control of cellular growth, 
crosstalk has been implicated in the inhibition of cancer cell hyperplasia (32, 60).  
Therefore, it is intriguing to speculate that crosstalk may exist between PKA and AMPK 
in VSM and that this crosstalk may be of biological significance in its ability to modulate 
VSM growth.   
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The purpose of this study was to further characterize the AMPK and PKA signaling 
pathways and to determine what role(s) they play in the collaborative inhibition of VSM 
growth.  Our hypothesis was that AMPK and PKA possess biochemical crosstalk and, in 
turn, may act cooperatively to inhibit VSMC proliferation and migration.  Novel results 
show that AMPK controls VSMC proliferation and migration and that these events are 
regulated at least in part by PKA.  These findings offer insight to a potential metabolic 
signaling network that may provide new therapeutic targets for control and potential 
reduction of vascular growth disorders. 
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Results 
 
AMPK enhances PKA activity 
Initial experiments focused on activation of AMPK in rat primary VSMCs.  Treatment 
of cells with 1 mM of the AMPK agonist AICAR (60 min), a concentration previously 
documented to effectively induce AMPK activity in vascular cells without observable 
side-effects (14, 29), significantly enhanced catalytic phosphorylation (121) of AMPK 
Thr172 (Fig. 4.1A) as well as acetyl Co-A carboxylase (ACC) at Ser80 (Fig. 4.1B), a 
traditional marker of AMPK activity (120).  Both basal and AICAR-stimulated pAMPK-
Thr172 and pACCSer80 were inhibited by 30 min pre-treatment with Compound C (CC; 
10 uM), a selective AMPK inhibitor established for use in VSM (14, 97, 103).  
Intriguingly, inhibition of PKA with PKI (10 uM) also reversed AICAR-induced increases 
in AMPK-Thr172 and ACC-Ser80 phosphorylation (Figs. 4.1A, 4.B).  In agreement, 
using an AMPK-specific activity assay AICAR induced a significant increase in AMPK 
activity that was reversed by CC and PKI under stimulated conditions and by CC under 
basal conditions (Fig. 4.1C).   
 
 
 
 
 
 
 
Figure 4.1 
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Figure 4.1.  AICAR increases AMPK signaling in rat primary VSMCs as measured via InCell 
Western blotting.  Cells were treated with AICAR (1 mM), Compound C (CC; 10 uM) or their 
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combination for 60 min and AMPK Thr172 phosphorylation (A), ACC Ser80 phosphorylation (B), and 
AMPK activity (C) were measured.   AICAR significantly increased phosphorylation of both AMPK Thr172 
(A) and ACC Ser80 (B) as well as AMPK activity (C), all in CC-reversible fashion.  CC also significantly 
reduced basal levels of phosphorylated AMPK Thr172, ACC Ser80 and AMPK activity.  In all cases 
addition of the PKA-inhibitor PKI significantly decreased AMPK signaling and activity.  Expression data 
were normalized to DNA content (Draq 5/Sapphire 700) and presented as phosphorylated AMPK/total 
AMPK (A) or phosphorylated ACC/total ACC (B).  Activity was measured via absorbance at 450 nm.  P 
values less than 0.05 were considered statistically significant for n=5-7 per group.  * p<0.05 compared to 
control; *** p<0.001 compared to control; # p<0.05 compared to respective activator treatment.  
 
Considering relative novelty of the In-Cell Western approach, traditional ECL-based 
Western blotting was used in primary cell lysates to support In-Cell Western results for 
these initial experiments.  VSMC lysates were probed for pAMPK Thr172 and pACC 
Ser80 as indicators of AMPK activity.  As shown in Figure 4.2, AICAR (1 mM, 60 min) 
increased AMPK catalytic phosphorylation and downstream ACC signaling as 
documented through ECL-based Western blotting (Figs. 4.2A and 4.2B).  AICAR-
mediated increases in pAMPK and pACC were then reduced to control levels in the 
presence of CC (data not shown).  These findings confirm our In-Cell Western results 
and establish utility of the In-Cell Western approach in primary VSM preparations.  
 
 
 
 
Figure 4.2 
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Figure 4.2.  AICAR increases AMPK signaling in rat primary VSMC lysates as measured via ECL-
based Western blotting.  Cells were treated with AICAR (1 mM) for 60 min and AMPK Thr172 
phosphorylation (A) and ACC Ser80 phosphorylation (B) were measured by traditional ECL-based 
Western blotting using IR-linked antibodies.  AICAR significantly increased phosphorylation of both AMPK 
Thr172 (A) and ACC Ser80 (B).  Phosphorylated protein levels were normalized to α-tubulin and data 
presented as fold change over control values.  P values less than 0.05 were considered statistically 
significant for n=3 per group.  ** p<0.01 compared to control. 
 
Studies were then performed to evaluate the influence of AMPK on PKA signaling.  
AICAR induced a significant increase in vasodilator-stimulated phosphoprotein (VASP) 
Ser157 phosphorylation, a reported marker of active PKA (22, 47), and this was 
completely reversed by CC (Fig. 4.3A).  Additionally, co-treatment of AICAR with a PKA 
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inhibitor PKI (10 uM; 60 min) also reversed AICAR-induced phosphorylation of VASP 
Ser157 (Fig. 4.3A).  Furthermore, using an activity assay AICAR induced a significant 
increase in PKA activity which was also fully reversed by CC and PKI (Fig. 4.3B).  
Neither basal levels of pVASP Ser157 nor PKA activity were affected by CC.   
 
Figure 4.3 
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Figure 4.3.  AMPK enhances PKA activity.  Cells were treated with AICAR (1 mM), Compound C (CC; 
10 uM) or a combination of both, and/or PKI (10 uM) for 60 min, and phosphorylation of VASP at Ser157 
(A) and PKA activity (B) were measured.  In-Cell Western analysis revealed that AICAR significantly 
increased VASP Ser157 phosphorylation (A).  A PKA activity assay shows that AICAR increased PKA 
activity (B).  Both analyses revealed full reversal with concomitant CC and/or PKI.  Data are presented as 
phosphorylated VASP/total VASP and normalized to DNA content (Draq 5/Sapphire 700) or absorbance 
at 450 nm for activity.  P values less than 0.05 were considered statistically significant for n=5-7 per 
group. *** p<0.001 compared to control; # p<0.05 compared to respective activator treatment. 
 
PKA preserves AMPK activity 
While phosphorylation of PKA at Thr197 is suggested to be indicative of catalytic 
activity (98), neither the adenylyl cyclase agonist Forskolin (FSK, 10 uM; 60 min) nor 
AICAR induced changes in phosphorylation of this site (data not shown).  However, 
treatment of VSMCs with FSK with or without the broad phosphodiesterase (PDE) 
inhibitor IBMX (10uM; 60 min) induced significant increases in pVASP Ser157,  which 
were reversed by the PKA inhibitor PKI (10 uM; Fig. 4.4A).  In addition, using an activity 
assay, while FSK alone induced a non-significant increase in PKA activity, addition of 
IBMX induced a significant increase in PKA activity that was reversed by PKI (Fig. 
4.4B). Additionally, concomitant treatments of FSK and AICAR significantly increased 
PKA activity (Fig. 4.4B).    
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Figure 4.4 
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Figure 4.4.  FSK increases PKA signaling in rat primary VSMCs.  Cells were treated with 
combinations of FSK (10uM), PKI (10 uM),  IBMX (10 uM), and/or AIC (1 mM) for 60 min and pVASP 
Ser157 phosphorylation and PKA activity were determined.  In-Cell Westerns revealed that FSK 
significantly increased pVASP Ser157 alone or in the presence of IBMX and/or AICAR, and these were 
largely reversed with the PKA inhibitor PKI (A).  A PKA activity assay revealed that FSK with IBMX or AIC 
synergistically increased PKA activity (B).  Data are presented as phosphorylated VASP/total VASP and 
normalized to DNA content (Draq 5/Sapphire 700) or absorbance at 450 nm for activity.  P values less 
than 0.05 were considered statistically significant for n=3-5 per group.  *** p<0.001 compared to control; # 
p<0.05 compared to respective activator treatment.  
 
Next, studies were performed to evaluate if PKA mediates changes in AMPK 
signaling.  FSK alone failed to alter pAMPK Thr172; however, when PDE activity was 
inhibited by IBMX, a significant increase in pAMPK Thr172 was observed (Fig. 4.5A).  
Intriguingly, synergistic responses in pAMPK Thr172, pACC Ser80, and specific AMPK 
activity were observed with co-treatments of FSK and AICAR (Fig. 4.5).  Also of note, 
PKI alone induced a significant inhibitory effect on basal AMPK activity, which returned 
to control levels with FSK co-treatment (Figs. 4.5A, 4.5C).   
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Figure 4.5 
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Figure 4.5.  PKA increases AMPK activity in VSMCs.  Cells were treated with FSK (10 uM), PKI (10 
uM) or a combination of FSK and PKI or IBMX (10 uM) or AIC (1 mM) for 60 min.  Phosphorylation of 
AMPK Thr172 and ACC Ser80 were measured by In-Cell Western (A) and (B) and AMPK activity was 
measured by pAMPK-specific activity assay (C).  FSK alone failed to significantly increase AMPK Thr172 
or ACC Ser80 phosphorylation or AMPK activity; however, in the presence of IBMX or AICAR all were 
significantly elevated.  PKI alone significantly reduced both pAMPK Thr172 and activity.  Data are 
presented as phosphorylated AMPK/total AMPK and normalized to DNA content (Draq 5/Sapphire 700) 
or absorbance at 540 nm for activity.  P values less than 0.05 were considered statistically significant for 
n=5-7 per group.  * p<0.05 compared to control; *** p<0.001 compared to control.  
 
Considering that phosphorylation at Ser485 has been associated with an inhibition of 
AMPK activity (69, 102), we investigated pAMPK Ser485 expression under both AMPK- 
and PKA-stimulated and -inhibited conditions.  In primary VSMCs, AICAR induced a 
significant increase in pAMPK Ser485, which was fully reversed by CC (Fig. 4.6A).  CC 
alone failed to significantly alter basal pAMPK Ser485 levels.  While FSK with or without 
IBMX failed to significantly alter Ser485 phosphorylation, treatment with PKI alone 
significantly reduced basal pAMPK Ser485, which returned to control levels with 
concomitant FSK treatment (Fig. 4.6B).   
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Figure 4.6 
 
 
 
Figure 4.6.  AICAR increases phosphorylation of AMPK at Ser485 in PKA-independent fashion.  (A) 
Cells were treated with AICAR (1 mM), Compound C (CC; 10 uM) or a combination of both for 60 min, or 
(B) with FSK (10 uM), PKI (10 uM) or a combination of both, or IBMX (10 uM), or AICAR (1 mM) for 60 
min.  In-Cell Western analyses revealed that (A) pAMPK Ser485 was elevated with AICAR in a CC-
reversible fashion.  While FSK with/without IBMX had no effect on pAMPK Ser485, FSK + AICAR did 
significantly increase pAMPK Ser485.  Intriguingly, PKI alone significantly decreased Ser485 
phosphorylation.  Data are presented as phosphorylated AMPK/total AMPK and normalized to DNA 
content (Draq 5/Sapphire 700).  P values less than 0.05 were considered statistically significant for n=5-7 
per group.  * p<0.05 compared to control; *** p<0.001 compared to control; # p<0.05 compared to 
respective activator treatment.  
 
 
 
	    63	  
PKA Inhibits Protein Phosphatases 
Serine/Threonine protein phosphatases (PPs), in particular PP-2A and PP-2C (51), 
have been reported to negatively modulate AMPK activity via kinase dephosphorylation.  
Therefore, we assessed the ability of PKA to inhibit Ser/Thr PP activity as a possible 
mechanism of PKA-mediated modulation of AMPK activity.  Surprisingly, treatment of 
VSMCs with AICAR steadily increased global PP activity in significant fashion compared 
to vehicle-treated control lysates (Fig. 4.7A).   Intriguingly, FSK treatment completely 
inhibited global PP activity in VSMC lysates compared to controls (Fig. 4.7A). With 
addition of NiCl2 (1 mM) to the reaction buffer to specifically monitor PP-2A activity (72), 
we found that AMPK specifically activated PP-2A in AICAR-treated lysates compared to 
controls while no differences were detected in FSK-treated cells (Fig. 4.7B).  Likewise, 
when MgCl2 (20 mM) was added to the reaction buffer to selectively monitor PP-2C 
(72), we found that FSK specifically and completely inhibited PP-2C levels compared to 
controls with no differences detected in AICAR-treated lysates (Fig. 4.7C).  Importantly, 
cumulative reductions in PP activity observed in these experiments (global, PP-2A, PP-
2C) were reversible with simultaneous CC- or PKI-inhibition of AMPK or PKA, 
respectively (data not shown for clarity).  
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Figure 4.7 
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Figure 4.7.  PKA inhibits global and isoform-specific Ser/Thr phosphatase activity.  Cell lysates 
were prepared from cells treated with AICAR (1 mM), or a combination of both AICAR and Compound C 
(CC; 10 uM) for 60 min, or with FSK (10 uM), or a combination of FSK and PKI (10 uM) for 60 min.  
Phosphatase activity of diluted (1:10) lysate samples was measured by DiFMUP fluorescence at 452 nm 
after 10 minutes of incubation in the dark.  Activity analysis revealed that AICAR induced while FSK 
inhibited global Ser/Thr phosphatase activity compared to control values (A).  With addition of NiCl2 (1 
mM) to the reaction buffer, PP-2A-specific activity was tested and revealed that AICAR significantly 
elevated PP-2A activity (B).  Similarly, with addition of MgCl2 (20 mM), DTT (2 mM), and EGTA (1 mM) to 
the assay buffer, PP-2C-specific activity was assessed and revealed that FSK significantly inhibited its 
activity (C).  Two-way ANOVA with Tukey’s post-hoc testing was used for multiple comparisons across 
time points as well as within each treatment group.  P values less than 0.05 across time within each 
group were considered statistically significant for n=3 per group.  ** p<0.01 compared to control. 
 
Cooperative signaling inhibits VSMC proliferation and migration 
The functional impact of these signaling events was assessed in VSMCs by 
examination of chemotactic cell migration and cellular proliferation.  The influence of 
AMPK signaling on PDGFβ-stimulated cell migration was assessed using a modified 
Boyden transwell chemotactic assay over 18 hours.  AICAR (1 mM) significantly 
reduced the number of migratory cells which was fully reversed with CC (Fig. 4.8).  
Interestingly, while only a trend (p=0.102) towards anti-migration was observed with 
FSK (10 uM) across the entire 18 hour experiment, two-way ANOVA revealed that the 
net migration at 18 hours was statistically significant compared to controls and was 
reversed with PKI (Fig. 4.8).  Of note, both CC and PKI alone showed no significance 
across time or at 18 hours compared to vehicle controls (data not shown for clarity). 
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Figure 4.8 
 
 
Figure 4.8.  AMPK inhibits VSMC migration.  Cells were labeled with CellTracker Green and treated 
throughout the assay with AICAR (1 mM), Compound C (CC; 10 uM) or a combination of both for 60 min, 
or with FSK (10 uM), PKI (10 uM), or a combination of both for 60 min, and cell migration was determined 
using a modified Boyden chamber apparatus and bottom-read fluorescence at 525 nm through 18 hours.  
AICAR significantly reduced cell migration across the entirety of the experiment and was reversed by CC.  
When looking across all time points, FSK had no significant effect on cell migration (p = 0.102); however, 
net migration at time=18 hours was significantly reduced with FSK.  The mean score of the best curve fit 
at 18 hours is portrayed by histogram.  Significance was determined by two-way ANOVA (with Tukey’s 
post-hoc testing for multiple comparisons) across the entirety of the 18 hour timeframe and at 18 hours 
with all time points compared to vehicle.  P values less than 0.05 across time within each group were 
considered statistically significant for n=5-8 per group.  **= p<0.01 compared to control; *** p<0.001 
compared to control; # p<0.05 compared to respective activator treatment.  
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Cell cycle progression and cell proliferation and viability were examined by flow 
cytometry and automated cell counting with trypan blue exclusion staining, respectively.  
Cell cycle analysis following 24 hour serum stimulation revealed AICAR significantly 
inhibited progression of cells from the S- to G2/M-phase, manifested as reduced cell 
numbers in G2/M and elevated cell numbers in S (Figs. 4.9A, 4.9B), and these were fully 
reversed by CC (Fig. 4.9A).  FSK did not significantly reduce G2/M cell populations or 
increase G0/G1-phase cells (Figs. 4.9A, 4.9B).  Automated cell counts after 48 hour 
serum stimulation revealed that AICAR significantly reduced cell numbers (Fig. 4.9C); 
however, CC failed to reverse this effect (data not shown).  As with the cell cycle data, 
while a trend was observed FSK alone did not significantly alter cell numbers compared 
to vehicle controls (Fig. 4.9C).   
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Figure 4.9 
Figure 4.9.  AMPK induces cell cycle arrest and inhibits VSMC proliferation.  Cells were treated with 
AICAR (1 mM), with/without Compound C (CC; 10 uM), or with FSK (10 uM) with/without PKI (10 uM) 
following overnight quiescence.  Cell cycle progression was analyzed by flow cytometry using the DNA 
stain propidium iodide after 24 hours (A) and cell numbers were quantified after 48 hours by automated 
cell counting and trypan blue exclusion (B).   Representative peaks from flow cytometry and histograms of 
these data illustrate that AICAR significantly inhibits cell cycle progression from S to the G2/M phase, 
revealed by increased numbers in S and reduced numbers in G2/M (A) and (B), and these were fully 
reversed by CC (A).  Cell cycle analysis revealed that FSK had no effect on cell cycle progression in 
primary VSMCs (A) and (B).  Cell count analysis also revealed that AICAR significantly reduced cell 
numbers after 48 hours, and while a trend was observed, two-way ANOVA reveals that FSK had no 
significant effect on cell numbers after 48 hours (C).  P values less than 0.05 were considered statistically 
significant after multiple comparisons and two-way ANOVA for n=3-5 per group.  ** p<0.01 compared to 
control; *** p<0.001 compared to control (control comparison was made within each stage of the cell cycle 
for cell cycle analysis). 
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Discussion 
 
Findings in this study support our hypothesis that AMPK, in conjunction with PKA, 
has capacity to inhibit growth of VSM.  We show that AMPK inhibits proliferation and 
migration of rat primary VSMCs and mechanistic data suggest that these growth-
mitigating effects of AMPK are at least partly regulated by PKA.  Novel findings also 
reveal that AMPK can reciprocally modulate PKA activity, suggesting that crosstalk 
exists between these two pivotal signaling factors.  It has been reported in adipocytes 
and endothelial cells that a biochemical relationship exists between AMPK and PKA 
(19, 42, 52); however, this relationship has not been established in VSM.  Since both 
cAMP/PKA and AMPK act to regulate cellular metabolism in response to intra- and 
extra-cellular signals (16, 19, 21, 80, 119), it is reasonable to speculate that a signaling 
relationship exists between the two signaling cascades in response to energy-
consuming cellular processes as proliferation and migration.  A synergistic relationship 
between AMPK and PKA has been suggested in the regulation of cancer growth (32, 
60), and each factor has been implicated individually in VSM growth inhibition (43, 47, 
67); therefore, based on the current study we propose a cooperative relationship exists 
between AMPK and PKA in the control of VSM growth.  Data presented here support 
our theory that AMPK acts to inhibit VSM growth and that PKA acts as an adjuvant to 
maintain and/or possibly enhance this capacity.   
Using rat primary VSMCs, AMPK expression and activity were successfully and 
specifically induced with AICAR, and this positively influenced the PKA pathway (Figs. 
4.1 – 4.3).  Conversely, the PKA system was successfully induced using FSK, and this 
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led to increased AMPK activity.  Following establishment of treatments to specifically 
modulate AMPK and PKA activities (Figs. 4.1, 4.4), potential crosstalk between the two 
systems was investigated.  AICAR increased PKA activity in AMPK-specific fashion 
(Fig. 4.3), suggesting that AMPK has the ability to increase PKA activity in VSMCs.  
Paradoxically, as shown in Figure 4.5 PKA also has the ability to modulate AMPK 
activity.  Although we were unable to detect increases in AMPK Thr172 phosphorylation 
or AMPK activity from FSK alone, as has been reported in other tissues (19, 42, 63, 
102), under conditions of PDE blockade with IBMX FSK did increase both AMPK 
Thr172 phosphorylation and AMPK activity.  This may reflect robust basal PDE activity 
under cell culture conditions as described recently (2).  Additionally, a synergistic effect 
was observed with concomitant AICAR and FSK treatments, suggesting these two may 
indeed act cooperatively as biochemical signaling molecules.  Moreover, inhibition of 
PKA by PKI showed a significant reduction in both AMPK phosphorylation and activity, 
and these were partially restored with concomitant FSK treatment.  These findings 
suggest that PKA may not directly modulate AMPK activity by phosphorylation, but may 
do so indirectly in a non-Ser172-dependent mechanism, and thus may serve to maintain 
a basal level of AMPK activity under stimulated conditions.   
A suggested mechanism by which PKA may modulate AMPK activity in vitro is by 
inhibitory phosphorylation of AMPK at Ser485 (42, 69).  We tested AMPK Ser485 
phosphorylation under stimulated (10% FBS) and growth-arrested (0.5% FBS) 
conditions with or without AMPK or PKA induction.  Our findings reveal that AICAR not 
only increased catalytic T172 phosphorylation of AMPK but also significantly increased 
Ser485 phosphorylation which was completely reversed by CC (Fig. 4.6).  Furthermore, 
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PKA inhibition significantly reduced Ser485 phosphorylation, further suggesting a 
possible regulatory role of PKA on AMPK.  Serum-starved cells showed a similar but 
much lower Ser485 phospho-reduction in response to PKI, but failed to exhibit altered 
phosphorylation in response to AICAR, CC, and/or FSK treatments (data not shown).  
Our data suggest that AMPK Ser485 phosphorylation may act to modulate AMPK 
activity and that PKA may play an important role in regulating this site.  In agreement, 
Hurley and colleagues showed significant auto-phosphorylation of AMPK Ser485 in a 
cell-free system after just 10 min of incubation with ATP (42).  Therefore, expanding on 
these data we suggest that Ser485 may be a site for auto-phosphorylation and “self-
inhibition” of AMPK to fine-tune the dynamic metabolic conditions of stimulated cells on 
a minute-by-minute basis.   
For kinases, the balance between “on” and “off” is highly regulated and is largely 
mediated by dephosphorylation by specific protein phosphatases.  Phosphatase activity, 
in particularly PP-2A and PP-2C, are major contributors to the reduction of AMPK 
activity (51).  In this light, we examined the ability of PKA to inhibit global and isoform-
specific Ser/Thr phosphatase activity.  We show that PKA stimulation completely inhibits 
global PP activity and more specifically PP-2C activity in primary VSMC lysates (Fig. 
4.7).  Taken together with our earlier data showing that PKA inhibition by PKI 
significantly reduced pAMPK Thr172 and pAMPK Ser485, a non-kinase mechanism of 
PKA-mediated regulation of AMPK is suspected.  Therefore, we suggest that in VSMCs 
PKA may indirectly mediate AMPK activity via reduced PP-2C activity thus inhibiting 
kinase de-phosphorylation and de-activation.  Conversely, specific PP-2A activity was 
significantly increased in AICAR-treated cells (Fig. 4.7B).  While seemingly 
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counterintuitive, we and others (45) suggest that PP-2A may play an inhibitory role on 
cell cycle progression via inactivation of cyclin/CDK complexes providing a possible 
mechanism by which AMPK acts to inhibit cell cycle progression as our data show (Fig. 
4.9).  Taken together, these biochemical findings suggest for the first time in primary 
VSMCs that AMPK and PKA exhibit the capacity for synergistic crosstalk, a finding that 
may play significant roles in the proposed AMPK-mediated inhibition of VSM growth. 
Complementing these biochemical data, functional roles for the cooperative 
signaling between AMPK and PKA were examined.  Vascular smooth muscle 
proliferation and migration are functional mechanisms underlying aberrant vessel 
growth.  Data using a transwell chemotactic assay (Fig. 4.8) clearly show that AICAR 
significantly inhibits PDGFβ-stimulated VSMC migration.  This is the first report 
demonstrating ability of AMPK to inhibit migration of VSMCs.  Additionally, data show 
that AICAR increases the down-regulatory phosphorylation of VASP at Thr157 (Fig. 
4.3A), a protein responsible for actin polymerization, which provides an intriguing 
hypothetical mechanism for how AMPK disrupts actin dynamics required for migration.  
Interestingly, after two-way ANOVA evaluating time-dependent migration over 18 hours 
FSK had no significant effect on VSMC migration compared to controls; however, 
overall migration after 18 hours showed a significant FSK-mediated anti-migratory 
effect.  Importantly, the degree to which FSK induced these anti-migratory effects 
remained significantly higher (29.8 +/- 3.6) than the AICAR-mediated effects (8.9 +/- 
1.5) on VSMC migration.  These functional data support our biochemical data and 
together give further credence to our hypothesis that PKA may act to enhance AMPK 
activity in an indirect manner.  In light of these new findings, it is reasonable to postulate 
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that the heretofore PKA-mediated actions within VSMCs that act to modulate 
proliferation and migration (47) may indeed be AMPK-mediated.   
Upon activation, normally contractile VSMCs undergo a phenotypic change and 
become synthetic and proliferative.  With this in mind, cell cycle analysis after 24 hours 
and automated cell counting after 48 hours revealed that AICAR significantly decreased 
cell cycle progression resulting in a significant reduction in cell numbers (Fig. 4.9).  Of 
note, while AICAR-induced cell cycle inhibition was reversed with CC after 24 h, cell 
proliferation after 48 h was not affected.  A recent study by collaborating investigators 
revealed that CC alone has capacity to inhibit VSMC proliferation (63, 74), perhaps due 
to the irreversible inhibitory actions of CC on AMPK (33), and in the current study we 
observed powerful cytostatic effects of CC and AICAR that kept cell numbers at 
reduced levels.  Moreover, in our study while FSK failed to significantly alter cell cycle 
progression and cell proliferation, a trend toward cytostasis in PKI-reversible fashion 
was observed (Fig. 4.9).  AMPK has been suggested to promote cell senescence; 
however, these intriguing findings together with our biochemical data suggest that while 
PKA stimulation alone may not promote cytostasis, PKA may act to enhance AMPK 
activity thus supporting and/or promoting AMPK-mediated cytostasis.  These data 
provide further evidence for the importance of AMPK in the inhibition of serum-
stimulated VSMC growth and shed new light on a signaling network that may provide 
robust growth reduction in a more specific and targetable manner. 
In conclusion, novel data presented here provide ample evidence that AMPK and 
PKA communicate biochemically and act in concert as a signaling network capable of 
controlling growth of VSMCs.  This signaling crosstalk may be important in the control of 
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cellular metabolism as has been proposed by others (16, 19, 21, 80, 119), and our data 
highlight its potential importance in the control of VSM growth.  The schematic in Figure 
4.10 highlights the proposed cooperative relationship by which AMPK and PKA are 
believed to inhibit VSMC proliferation and migration.  We suggest that AMPK increases 
PKA activity and that PKA may independently or in turn inhibit Ser/Thr PP-2C activity, 
thus indirectly modulating AMPK activity.  Additionally, these data suggest that PKA 
may modulate AMPK activity by regulating phosphorylation of a proposed inhibitory 
AMPK Ser485 site.  These findings suggest a reciprocal and feed-forward mechanism 
by which PKA modulates AMPK activity in serum-stimulated VSMCs to further 
potentiate the anti-growth properties associated with AMPK.   
 
Figure 4.10 
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Figure 4.10.  Schematic depicting the proposed cooperative relationship between AMPK and PKA 
in the control of VSM growth.  In this diagram blunt lines represent proposed inhibitory while arrows 
represent proposed stimulatory mechanisms.  Those pathways that were not directly tested and remain 
part of the overall hypothesis of this report are presented as dashed lines.  Biochemical data described 
herein reveal that AMPK increases PKA activity and reciprocally, that PKA may modulate AMPK activity 
by regulation of proposed AMPK-inhibitory Ser485 phosphorylation.  Furthermore, data show that PKA 
abrogates Ser/Thr phosphatase-2C activity, which may play a crucial role in regulating AMPK activity.   
Functional data confirm that AMPK reduces VSMC growth by inhibiting cell proliferation and migration.  
Intriguingly, these data show an increase in reported PKA-specific VASP Ser157 phosphorylation, 
suggesting AMPK may act indirectly through increased PKA activation to inhibit VASP-directed actin 
polymerization necessary for cell movement.  Additionally, novel findings from this study suggest that 
AMPK increases PP-2A activity in VSMCs, which provides a possible mechanism for AMPK-mediated cell 
cycle inhibition, a reported function of PP-2A.  Altogether these findings illustrate important cooperative 
signaling between AMPK and PKA in serum-stimulated VSMCs that may further potentiate the anti-
growth properties associated with AMPK.   
 
In addition to its static effects on proliferation, we show for the first time that AMPK 
has capacity to inhibit VSMC migration, providing a functional mechanism for the 
prevention of VSMC-mediated vessel remodeling following disease or injury.  
Intriguingly, our data show an increase in proposed PKA-specific VASP Ser157 
phosphorylation, suggesting AMPK may indirectly through increased PKA activation to 
inhibit VASP-directed actin polymerization necessary for cell movement.  Additionally, 
novel findings from this study suggest that AMPK increases PP-2A activity in VSMCs, 
providing a possible mechanism for AMPK-mediated cell cycle inhibition, a reported 
function of PP-2A.  Altogether, these data elucidate a signaling network that has 
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potential clinical importance as a foundation for current therapeutics targeting VSM 
growth disorders.  
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Abstract 
 
Vascular growth disorders are a major contributing factor to cardiovascular disease, 
the leading cause of morbidity and mortality in the United States.  In this 
pathophysiologic process, growth factor activation of normally quiescent vascular 
smooth muscle cells (VSMCs) results in an aberrant proliferative and synthetic 
phenotype that can lead to vascular occlusion.  Transforming growth factor-beta (TGF-
β) is a multifunctional signaling protein capable of potent growth stimulation via its 
canonical Smad signaling cascade. Although Smad signaling is well characterized in 
many tissues, its exact role in vascular smooth muscle (VSM)-dependent proliferative 
disorders remains uncertain.  Recent data from our lab and others implicate the 
metabolic regulator AMP-activated protein kinase (AMPK) in the inhibition of VSMC 
proliferation.  Therefore, this study explored the hypothesis that AMPK inhibits VSMC 
proliferation by reducing TGFβ-mediated VSMC growth.  Treatment of rat VSMCs with 
the AMPK agonist AICAR significantly decreased TGFβ-mediated activation of pro-
synthetic Smad2 and Smad3 and increased expression of inhibitory Smad7 after 24 
hours.  Flow cytometry and automated cell counting revealed that AMPK activation 
specifically reversed TGFβ-mediated cell cycle progression at 24 hours and viable cell 
numbers at 48 hours. Mechanistically, induced TGFβ/Smad signaling increased both 
the G0/G1 cell cycle regulators cyclins D1 and E as well as their dependent kinases 
CDK4 and CDK2, respectively, while AMPK activation significantly reduced cyclins D1 
and E and CDKs 2 and 4 and was associated with an increase in the cytostatic CDK-
inhibitor p21.  Taken together, these findings provide ample evidence of a novel AMPK 
target in TGFβ/Smad signaling for the control of VSM growth and support continued 
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investigation of AMPK as a valuable therapeutic target aimed at reducing the 
progression of vascular growth disorders. 
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Introduction 
 
Transforming growth factor-beta1 (TGFβ1) is a multifunctional cytokine acting 
canonically through Smad signaling to exert its effects in a wide range of cell types.  In 
VSMCs, TGFβ has historically been considered to have anti-proliferative effects (3, 70, 
75, 78); however, recent findings suggest that TGFβ signaling stimulates growth in 
primary VSMCs (40, 56, 57, 85, 86, 104, 105, 108).  TGFβ elicits its effects by binding 
to cell-surface receptors, whereupon it stimulates the phosphorylation of cytoplasmic 
receptor-activated Smads (R-Smads) Smad2 and Smad3.  The activated R-Smads 
combine with the common Smad4 and the complex is transported to the nucleus to act 
on targeted, growth-regulatory genes (85, 88, 105, 125).  Moreover, the capacity of 
TGFβ to control cellular growth has been shown to be mediated, at least in part, by the 
cyclin-dependent-kinase (CDK) inhibitor p27 (75).  Additionally, it has been recently 
demonstrated that the pro-growth effects of TGFβ in VSMCs involve Smad3-mediated 
phosphorylation and nuclear export of p27 (108).  A further component of this signal 
transduction pathway is inhibitory Smad7 which suppresses TGFβ signaling by 
interfering with the activation of the R-Smads (85, 88, 125).  In light of these recent 
findings, the controversial nature of TGFβ/Smad signaling particularly in VSM justifies 
continued study and presents an attractive target for future therapeutic interests. 
To date, no studies have examined the potential role of AMPK in modulating TGFβ-
induced VSMC growth.  The purpose of this study then was to characterize the capacity 
of AMPK to modulate growth in response to TGFβ stimulation in rat VSMCs.  Our 
hypothesis was that AMPK reduces TGFβ-stimulated VSMC growth via reduction in 
Smad signaling and via inhibitory modulation of cell cycle regulators.  Novel results 
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provide evidence for a new target in AMPK for the control of vascular growth and shed 
light on the role of TGFβ signaling in VSM.  Altogether, our findings provide further 
support for the continued investigation of AMPK as a valuable target for therapies aimed 
at reducing the progression of vascular growth disorders. 
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Results 
 
TGFβ promotes VSMC growth 
Growth control of VSM has been previously suggested to be dependent at least in 
part on mechanisms involving cyclic AMP (47, 101) or TGFβ (3, 75, 78).  We recently 
observed that cyclic AMP in communication with the metabolic gauge AMPK also has 
capacity to exert growth control of VSM (101).  Considering that the canonical growth-
regulating TGFβ pathway operates primarily through Smad signaling (85, 88, 105, 125), 
in the current study we explored whether AMPK controls growth of VSM through 
mechanisms involving TGFβ and Smads.   
The pleiotropic and often discordant nature of TGFβ signaling to control tissue 
growth demands attention.  Historically considered anti-proliferative in a variety of cell 
types (3, 8, 70, 75, 78), new findings suggest that TGFβ1 through Smad stimulates 
growth in primary VSMCs (85, 86, 104, 105, 108).  Adding to this uncertainty, in cultured 
cells TGFβ1 is suggested to switch between growth stimulation and growth suppression 
depending on concentration (5, 85) and cell density (40).  Thus, our initial experiments 
aimed to verify the capacity of TGFβ1 to induce Smad signaling and to determine its 
ability to regulate growth in rat VSMCs.  Using flow cytometry and automatic cell 
counting, cells treated with recombinant TGFβ1 (10 ng/ml) for 24 hours show 
significantly elevated levels of phosphorylated (at Thr8) Smad2 and phosphorylated (at 
Ser423/425) Smad3 (each normalized to total Smad2 or Smad3, respectively) and 
moderately (20%) decreased expression of inhibitory Smad7 compared to cells treated 
with vehicle controls (Figs. 5.1A, 5.1B, 5.1C).  Next, recombinant TGFβ1 (10 ng/ml) 
significantly increased cell numbers in the G2/M phase of the cell cycle after 24 hours 
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(Fig. 5.2), significantly elevated viable cell numbers after 48 hours (Fig. 5.3), and 
significantly increased growth-promoting cell cycle regulatory cyclins D1 and E (Fig. 5.4) 
and the cyclin-dependent kinase (CDK) 2 and CDK4 (Fig. 5.5) compared to vehicle 
controls.  Interestingly, TGFβ1 (10 ng/ml) only marginally reduced expression of the 
CDK inhibitors p21 and p27 compared to vehicle controls (Fig. 5.6).  Nonetheless, these 
initial findings verify that TFGβ1 operates through Smad signaling and serves to 
stimulate growth in cultured VSMCs. 
 
AMPK inhibits TGFβ1-mediated Smad signaling 
We recently demonstrated that activation of AMPK via the AMP mimetic AICAR (1 
mM) effectively reduces serum-stimulated proliferation and migration of rat primary 
VSMCs (100, 101).  In the current study in an effort to examine the influence of AMPK 
on TGFβ1 signaling and TGFβ1/Smad-dependent VSMC growth, we treated cells with 
AICAR (1 mM) for 24 hours in the presence or absence of recombinant TGFβ1 (10 
ng/ml) and then evaluated Smad signaling and indices of vascular growth.  As shown in 
Figure 5.1, AICAR alone had modest effects on phosphorylated Smad2 or 
phosphorylated Smad3 yet significantly increased Smad7 compared to vehicle controls.  
Interestingly, AICAR in the presence of TGFβ1 significantly reversed the increases in 
phosphorylated Smad2 and phosphorylated Smad3 observed with TGFβ1 alone.  
Moreover, concomitant AICAR and TGFβ1 significantly increased Smad7 compared to 
both vehicle and sole TGFβ1 treatments (Fig. 5.1C).   
 
Figure 5.1 
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Figure 5.1.  AMPK inhibits TGFβ1 signaling.  Rat VSMCs were treated with recombinant TGFβ1 (10 
ng, 60 min) and/or AICAR (1 mM, 60 min) and Smad proteins were analyzed by immunofluorescence and 
flow cytometry.  TGFβ1 alone significantly induced expression of phosphorylated Smad2 and 
phosphorylated Smad3 (each normalized to total Smad2 or Smad3 protein, respectively) which were fully 
reversed with AICAR dosing.  TGFβ1 alone moderately reduced expression of inhibitory Smad7, but 
AICAR alone or in the presence of TGFβ1 significantly increased Smad7.  Data are presented as 
pSmad/total Smad and normalized to total protein, n = 3-5 per group.  P values less than 0.05 were 
considered statistically significant.  *= p<0.05 compared to control; # = p<0.05 compared to TGFβ1 alone; 
∆ = p<0.05 compared to AICAR alone. 
 
AMPK inhibits TGFβ1-induced VSMC proliferation 
To determine the extent to which AMP kinase mediates TGFβ1-induced VSM 
growth, we analyzed cell cycle progression via flow cytometry under non-stimulated and 
TGFβ1-stimulated conditions in the absence or presence of AICAR.  First, supporting 
our previous observations (100, 101) AICAR alone induced significant increases in S-
phase cell numbers and significantly reduced G2/M-phase cell numbers compared to 
vehicle controls (Fig. 5.2).  TGFβ1 alone (10 ng/ml) induced significant increases in cell 
numbers in G2/M which were completely reversed with concomitant AICAR (1mM) after 
24 hours (Fig. 5.2).  No significant changes were observed in G0/G1 following TGFβ1 
and/or AICAR dosing at this time point.  In complement, automated cell counting after 
48 hours revealed that TGFβ1 alone induced significant increases in cell numbers that 
were completely abrogated by concomitant AICAR (Fig. 5.3).  As expected, AICAR 
alone significantly reduced cell numbers compared to vehicle controls at this time point.  
Notably, no significant differences in cell viability were detected for any individual or 
combined TGFβ1/AICAR treatment groups (data not shown). 
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Figure 5.2 
	  
	  
	  
	  
	  
 
Figure 5.2.  AMPK reverses TGFβ1-induced cell cycle progression.  Rat VSMCs were treated with 
TGFβ1 (10 ng) and/or AICAR (1 mM) for 24 hours following overnight quiescence.  Cell cycle progression 
was analyzed by flow cytometry using Draq5.  TGFβ1 induced cell cycle progression as indicated by 
increased G2/M cell populations.  AICAR significantly inhibited cell cycle progression revealed by 
insignificant increases in G0/G1, significant increases in S-phase, and significant reduction of G2/M cell 
numbers.  P values less than 0.05 were considered statistically significant after multiple comparisons and 
two-way ANOVA for n=3-5 experiments.  *** = p<0.001 compared to control; # = p<0.05 compared to 
TGFβ1 alone. 
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Figure 5.3 
	  
 
Figure 5.3.  AMPK reverses TGFβ1-induced cell proliferation.  Cells were treated with TGFβ1 (10 ng) 
and/or AICAR (1 mM) for 48 hours following overnight quiescence.  Cell numbers were quantified by 
automated cell counting and trypan blue exclusion staining.  TGFβ1 alone significantly increased cell 
numbers while AICAR alone significantly reduced cells numbers compared to vehicle controls.  
Concomitant TGFβ1 and AICAR revealed significant reduction in cell numbers compared to sole TGFβ1 
treatment.  Trypan blue exclusion failed to detect any differences in cell viability in any treatment group 
(data not shown).  P values less than 0.05 were considered statistically significant after multiple 
comparisons and two-way ANOVA for n=3-5 experiments.  ** = p<0.01 compared to control; # = p<0.05 
compared to TGF-β1 alone. 
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AMPK reverses TGFβ1-induced cell cycle proteins 
In order to determine the mechanisms by which AMPK inhibits TGFβ1-induced cell 
cycle progression and cell proliferation, we investigated the expression profile of key cell 
cycle regulators in the presence or absence of TGFβ1 with/without AICAR.  TGFβ1 
alone induced significant increases in the cell cycle promoters cyclin D1 and cyclin E 
(Figs. 5.4A, 5.4B) as well as in catalytic CDK2 and CDK4 (Fig. 5A, 5B) compared to 
vehicle controls after 24 hours.  While AICAR had no effect on non-stimulated cyclin 
expression, a nonsignificant reduction in CDK2 (p=0.07) and a significant reduction in 
CDK4 were observed following sole AICAR dosing (Figs. 5.5A, 5.5B).  Notably, in co-
treated cells AICAR reversed TGFβ1-induced increases in cyclins D and E and CDK2 
and CDK4 (Figs. 5.4A, 5.4B, 5.5A, 5.5B, respectively).  Interestingly, no changes were 
observed in CDK6 expression following TGFβ1 or AICAR stimulation (Fig. 5.5C).  
Additionally, we investigated the CDK inhibitors p21 and p27 after 24 hours and found 
that AICAR increased p21 expression under both TGFβ1-stimulated and non-stimulated 
conditions (Fig. 5.6A).  AICAR also significantly increased p27 content, which was 
reversed with concomitant TGFβ1 (Fig. 5.6B).  TGFβ1 alone failed to significantly alter 
p21 or p27 expression compared to vehicle controls.     
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Figure 5.4 
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Figure 5.4.  AMPK inhibits TGFβ1-induced cyclin expression.  Cells were treated with recombinant 
TGFβ1 (10 ng) and/or AICAR (1 mM) for 24 hours following overnight quiescence.  Cell cycle regulatory 
cyclins D1 and E were analyzed by immuno-fluorescence with flow cytometry.  TGFβ1 alone induced 
expression of cyclins D1 and E, which were significantly reversed in the presence of AICAR.  Data are 
presented as total cyclin content normalized to total protein, n = 3-5.  P values less than 0.05 were 
considered statistically significant.  *= p<0.05 compared to control; ** = p<0.005 compared to control; *** 
= p<0.001 compared to control; # = p<0.05 compared to TGF-β1 alone. 
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Figure 5.5 
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Figure 5.5.  AMPK inhibits TGFβ1-induced CDK expression.  Cells were treated with recombinant 
TGFβ1 (10 ng) and/or AICAR (1 mM) for 24 hours following overnight quiescence.  Catalytic cell cycle 
regulatory cyclin dependent kinase (CDK)2, CDK4 and CDK6 were analyzed by immunofluorescence with 
flow cytometry.  TGFβ1 alone induced expression of the cyclin E agonist CDK2 and the cyclin D agonist 
CDK4, which were both significantly reversed in the presence of AICAR.  No changes were observed in 
CDK6 expression with any treatment.  Data are presented as total CDK normalized to total protein, n = 3-
5.  P values less than 0.05 were considered statistically significant.  *= p<0.05 compared to control; # = 
p<0.05 compared to TGFβ1 alone. 
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Figure 5.6 
 
 
Figure 5.6.  AMPK induces CDK inhibitor expression.  Cells were treated with recombinant TGFβ1 (10 
ng) and/or AICAR (1 mM) for 24 hours following overnight quiescence.  Cyclin dependent kinase 
inhibitors p21 and p27 were analyzed by immunofluorescence with flow cytometry.  AICAR alone induced 
significant elevation of p21 and p27; however, only p21 remained significantly elevated following TGFβ1 
treatment.  Data are presented as total p21 or p27 normalized to total protein, n = 3-5.  P values less than 
0.05 were considered statistically significant.  *= p<0.05 compared to control; **= p<0.005; # = p<0.05 
compared to TGFβ1 alone; ∆= p<0.05 compared to AICAR alone. 
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Discussion 
 
Data presented in this study support our hypothesis that AMPK significantly inhibits 
VSMC growth through a mechanism at least partly dependent upon the TGFβ/Smad 
signaling pathway.  Novel findings show that AMPK, stimulated to biologically active 
levels by AICAR as established recently (100, 101), serves to markedly reduce 
TGFβ/Smad signaling and its growth-stimulating effects in VSMCs.  We found AMPK to 
reverse TGFβ-mediated increases in Smad2 and Smad3 and its negative effects on 
Smad7, to reverse exaggerated cell numbers in G2/M as well as total viable cell 
numbers, to reduce expression of growth-promoting cyclins D and E and CDK2 and 
CDK4, and to stimulate expression of cytostatic p21.  These findings are among the first 
to suggest that AMPK inhibits VSMC growth associated with the proliferative and 
synthetic TGFβ signaling network.  This research provides novel insights into AMPK 
signaling as a biologically capable system to offer significant remediation of TGFβ-
induced vascular growth.  Smooth muscle-mediated vascular remodeling is integral in 
the onset and complication of vasculoproliferative diseases (44, 62, 77); therefore, 
growth-targeting therapeutic strategies are highly relevant and important clinically.  Data 
presented here in conjunction with our recently published findings (100, 101) strongly 
support AMPK as a biologically active signaling molecule within VSM that is capable of 
inhibiting pathologic TGFβ-induced cell cycle progression and proliferation.  
TGFβ is suggested to promote VSMC growth via activation of its canonical Smad 
signaling cascade (85, 88, 104, 105, 125).  In this process, TGFβ (following binding to 
the TGFβ1 Receptor I) phosphorylates receptor-activated Smad3 and Smad2, which 
then bind to the common Smad4 to form an activated complex which translocates to the 
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nucleus to activate or repress transcription of growth-regulatory genes.  At the same 
time, Smad3 activates inhibitory Smad7 in negative feedback to antagonize TGFβ 
signaling.  Data presented here demonstrate the ability of TGFβ to increase VSMC 
proliferation determined through cell cycle progression (Fig. 5.2) and cell proliferation 
(Fig. 5.3).  TGFβ alone significantly increased both cell cycle progression as indicated 
by a doubling of cells entering the G2/M phase of the cell cycle as well as a ~50% 
increase in cell numbers after 48 hours.  Together these data support recent reports 
that TGFβ promotes proliferation in VSMCs (41, 85, 86, 104, 105, 108).  In both cases, 
and as we have previously reported (100, 101), AICAR alone significantly reduced cell 
proliferation, and here we show that AICAR is sufficient to prevent TGFβ-induced VSMC 
proliferation.  AMPK has previously been reported to possess anti-proliferative 
properties (23, 35, 61, 64, 100, 101); however, this report provides novel mechanistic 
understanding of AMPK and its ability to specifically prevent growth of VSMCs induced 
by TGFβ.  These findings offer new insight into a possible therapeutic target for the 
prevention of aberrant vascular growth as well as specific inhibition of TGFβ signal 
transduction which is traditionally suggested to promotes collagen synthesis and 
secretion, but also is suggested to have various off-target effects such as stimulating 
MAPKinases (56, 78, 104, 105, 126), RhoGTPases (86), and cdc42/Rac (41) which play 
critical roles in cell proliferation, growth and adhesion.  Vascular SMC growth and 
migration have been the focus of much research in our lab and others for their key role 
in the progression of vascular growth disorders; therefore, implication of AMPK as 
heretofore uncharacterized inhibitor of TGFβ signaling has great biological and clinical 
impact. 
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To determine possible mechanisms by which AMPK inhibits TGFβ signaling and cell 
growth we utilized immunofluorescence with flow cytometry to investigate the influence 
of AICAR treatment on the TGFβ/Smad network.  Figure 5.1 demonstrates that while 
AMPK alone has no effect on expression of Smad2 or Smad3, when AICAR was used 
in conjunction with TGFβ a complete reversal of TGFβ-induced increases of both 
Smad2 and Smad3 was observed.  Intriguingly, when VSMCs were treated with AICAR 
+/- TGFβ a significant increase in the expression of inhibitory Smad7 was apparent.  
These data suggest that while under basal conditions AMPK may play little or no role in 
regulating TGFβ receptor signaling; however, under cytokine-induced growth-provoking 
conditions AMPK plays a significant inhibitory role on TGFβ signaling by promoting the 
inhibitory actions of Smad7.  This increase in Smad7 inhibits oligomerization of 
pSmad2/pSmad3 with the cytoplasmic signal transducer Smad4.  Reducing the TGFβ 
signal transduction in this manner inhibits the translocation of the Smad oligomer into 
the nucleus thus inhibiting activation of growth-promoting gene transcription (85, 88).  
Together with our anti-proliferative data, we suggest that AMPK-mediated inhibition of 
TGFβ signal transduction by increasing Smad7 contributes to the reduction of cell cycle 
progression and cell proliferation. 
In order to determine mechanisms for the observed functional inhibition of AMPK on 
TGFβ signaling, we next investigated the role of TGFβ and AMPK on the G0/G1 cell 
cycle regulatory proteins cyclin D/CDK4/6, cyclin E/CDK2, and p21 and p27.  Early 
G0/G1-dependent cyclin D and late G0/G1-dependent cyclin E were both significantly 
elevated by TGFβ; however, concomitant treatment with AICAR significantly reduced 
both cyclin D1 and cyclin E compared to control and cytokine-induced conditions (Fig. 
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5.4).  Both cyclin D1-associated CDK4 as well as cyclin E-associated CDK2 were 
significantly elevated by TGFβ but were completely reversed to below basal levels with 
concomitant AICAR (Fig. 5.5).  Intriguingly, no change was observed in cyclin D-
associated CDK6, possibly suggesting that TGFβ promotes cell cycle progression in a 
cyclin D/CDK4- then cyclin E/CDK2-specific fashion.   Furthermore, AICAR elevated 
both CDK inhibitors p21 and p27; however, only p21 remained elevated following co-
treatment with TGFβ (Fig. 5.6).  Taken together, these data suggest that AMPK has 
ability to inhibit TGFβ-induced cell cycle progression via reduction in G0/G1 cyclin 
D/CDK4 and cyclin E/CDK2 complexes possibly through CDK inhibition via p21.  
While there may be some concern with the use of commercial rat VSMCs as used in 
this this study, we found that the endpoints analyzed in this study had no differences 
than what we’ve previously observed in rat primary VSMCs (100, 101).  Neither 
baseline nor AICAR-stimulated activation of AMPK nor phosphorylation of the 
downstream targets acetyl CoA carboxylase and vasodilator stimulated phosphoprotein 
was different in A7R5 VSMCs compared to primary cells as reported (100, 101).  
Therefore, we feel that the data presented in this study is fully representative of what 
would be expected in primary preparations and should be considered highly translatable 
and biologically relevant. 
Taken together, findings in this study suggest a discrete signaling network exists by 
which AMPK inhibits the proliferative signaling cascade elicited by TGFβ/Smad which is 
presented as a theoretical schematic in Figure 5.7.  Here we show that AMPK inhibits 
pSmad2/3 presumably by promoting Smad7.  This inhibition of TGFβ signaling results in 
reversal of TGFβ-induced G0/G1 cell cycle progression via inhibition of cyclins/CDKs D/4 
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and E/2 which we suggest is mediated by cytostatic, growth-inhibitory p21.  
Cumulatively, these data paint the picture of a novel and biologically important signaling 
cascade by which a metabolically activated protein such as AMPK has capability of 
inhibiting cytokine-induced pro-growth/pro-synthetic signaling events.  This has clear 
biological importance as a therapeutically desirable approach to reversing cell growth 
associated with various disease processes. 
 
Figure 5.7 
 
 
Figure 5.7.  Schematic depicting the proposed inhibitory actions of AMPK on TGFβ1-induced 
VSMC growth.  Data presented in this study suggest that AMPK has ability to inhibit TGFβ1-mediated 
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Smad signaling via promoting inhibitory Smad7 and by preventing growth-promoting Smad2/Smad3.  
Prevention of Smad2/3 phosphorylation and oligomerization with accessory Smad4 prevents their nuclear 
translocation and transcriptome activation of growth regulatory genes.  We propose a possible pro-
synthetic mechanism of TGFβ1/Smad signaling in VSMC in the promotion of cell cycle progression and 
cell proliferation through cyclinD/CDK4 and cyclinE/CDK2.  Additionally, AMPK possesses ability to 
enhance the CDK inhibitor p21 which acts to further inhibit TGFβ1-mediated G0/G1 cell cycle progression.  
Solid lines represent well supported signaling events previously characterized in the literature while 
dashed lines represent signaling events supported by novel findings from this study.  
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Abstract 
 
Abnormal vascular smooth muscle cell (VSMC) growth is a major contributor to 
vascular disease etiology.  We have previously reported that the metabolic switch AMP-
activated protein kinase (AMPK) has ability to inhibit vascular growth in vivo and in vitro. 
The microfilament-associated vasodilator-stimulated phosphoprotein (VASP) has been 
implicated in cell growth via its dynamic interaction with actin cytoskeleton and focal 
adhesion (FA) complexes, via increased Rho-A GTPase activity, and through Rho-A-
mediated serum response element (Sre)-dependent transcriptional activity.  Published 
data by our lab and others reveals direct signaling between AMPK and VASP; therefore, 
the hypothesis of this study is that AMPK reduces VSMC growth through a mechanism 
dependent upon inhibition of VASP.  Our data reveal that activation of AMPK by the 
AMP-mimetic AICAR in rat A7R5 VSMCs increases inhibitory Ser157 and Thr278 
phosphorylation of VASP with concomitant increased G- to F-actin ratio compared to 
vehicle control conditions.  Additionally, reduced catalytic Tyr397 phosphorylation of 
focal adhesion kinase (FAK) and increased cytostatic-associated paxillin were observed 
in AICAR treated VSMCs compared to controls.  Functionally, AICAR inhibited VSMC 
PDGF-stimulated transwell migration and serum-stimulated cell cycle progression after 
24 hours.  To determine if these events were VASP-dependent, we cultured lentiviral-
mediated VASP-deficient VSMCs and found that VASP deficiency reversed the AMPK-
mediated cell cycle inhibition and anti-migration observed in wild type cells.  Taken 
together, these findings suggest that AMPK has ability to reduce serum-stimulated 
VSMC growth by inhibiting VASP-directed actin cytoskeletal dynamics that play key 
roles in cell migration as well as transcriptional activity implicated in cell growth.  This 
 
	    103	  
discrete signaling network provides further insight into the anti-growth properties of 
AMPK and provides rationale for further exploration of AMPK as a target for the 
inhibition of vascular growth disorders. 
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Introduction 
 
The actin cytoskeleton is a highly dynamic structure that plays a vital role in directing 
cellular signaling events as well as mechanically regulating cell migration and 
proliferation.  Many of the pathologies associated with vasculoproliferative disorders 
such as, vessel hypertrophy, and restenosis following clinical intervention are attributed 
to phenotypic switching of vascular smooth muscle cells (VSMC) from a contractile to a 
synthetic state (44, 62, 77).  In this synthetic state VSMCs become proliferative and 
migratory and promote the synthesis and turnover of extracellular matrix.  This 
destabilization of the vessel wall leads to deleterious lesion formation and vessel 
stenosis associated with vascular growth disorders (11, 24, 34, 44, 62, 76, 77, 82).  
The actin-associated accessory protein vasodilator-activated serum phosphoprotein 
(VASP) is a key regulator of the actin cytoskeleton, serving to promote polymerization 
as an anti-capping protein.  As actin fibers grow, VASP delivers monomeric actin to the 
barbed end of the growing filament and acts to inhibit filament capping by capping 
proteins (4, 6, 10).  VASP has been implicated in the control of intra- and extra-cellular 
signaling events associated with cell migration and proliferation and transcriptional 
activity (4, 6, 7, 10, 15, 31, 91, 123, 129).  Due to its role as a signal transducer, 
differential VASP phosphorylation at Ser157, Ser239, and Thr278, which act to inhibit its 
activity, has been traditionally used as readout of protein kinase signaling (2, 7, 9, 47).  
Given its ability to be quickly turned on or off by phosphorylation, it is logical to think that 
investigating VASP as a downstream target of protein kinases capable of inhibiting 
VSMC growth could elucidate previously unclear signaling and growth control 
mechanisms within VSMCs and thus is the focus of this project.  In addition, we and 
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others have recently reported the ability of AMPK to specifically phosphorylate VASP (9, 
100, 101), suggesting this may offer insight into the mechanisms by which AMPK 
regulates vascular growth. 
Altogether, these reports strongly implicate the ability of AMPK to significantly 
regulate VASP activity and to inhibit VSMC growth.  Therefore, the purpose of this study 
was to investigate the hypothesis that AMPK acts to inhibit VSMC proliferation and 
migration and that it does so in VASP-dependent manner.  Data presented here support 
this notion and provide further evidence that AMPK has capacity to significantly regulate 
VSMC growth and has potential as a therapeutic target for the prevention and treatment 
of vasculoproliferative disorders. 
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Results 
 
AMPK specifically phosphorylates VASP 
Actin cytoskeleton-associated vasodilator-activated serum phosphoprotein (VASP) is 
implicated in the directionality of extra- to intra-cellular signaling events and in the 
regulation of focal adhesions and, via nucleotide exchange factor regulation, in the 
control of transcriptional activation (10, 31, 123, 129).  Site-specific VASP 
phosphorylation has also been used as readout of differential protein kinase signaling 
as we have recently reported (2, 47, 100, 101).  Moreover, we recently showed that 
AMPK has capacity to control differential VASP phosphorylation in the inhibition of 
growth in rat primary VSM cells (100, 101).  In the current study utilizing commercially-
available rat A7R5 VSMCs we verified these signaling events using the AMP mimetic 
AICAR (1mM, 1 hr) and found significant doubling of phosphorylation of both the PKA-
specific VASP Ser157 and the AMPK-specific VASP Thr278 (Fig. 6.1A).  As expected, 
there was no change in VASP Ser239 phosphorylation which has been previously 
reported to be PKG-dependant (2, 7, 9, 47).  Considering these data implicating VASP 
in the mechanisms of action of AMPK, in order to determine the extent to which VASP 
phosphorylation by AMPK plays a role in regulating cell growth we generated VASP-
deficient VSMCs using Lv-mediated shRNA directed against full-length VASP.  Figure 
6.1B is a representative Western blot performed on VSMC homogenates that illustrates 
efficient protein knockdown of VASP 24 hours post-transduction.  In this photo A, B, and 
C are replicates of Lv-shRNA-treated [(-)VASP] cells, NTC represents a non-targeting 
(scrambled) control, and Veh is the vehicle control (DMEM, 15% FBS, 
penicillin/streptomycin).  InCell Western blotting on adherent VSMCs was also 
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performed 48 hours post-transduction, and Figure 6.1C shows densitometric results for 
VASP protein expression.  In both ECL-based Western blotting (Fig. 6.1B) and ICW 
blotting (Fig. 6.1C) significant reduction in total VASP expression is clearly evident in 
the Lv-shRNA treated VSMCs compared to NTC and Veh controls.  Next, we examined 
VASP Ser157 and VASP Thr278 phosphorylation in normal and VASP-deficient cells in 
order to confirm site-specific VASP knockdown.  Significant loss of phosphorylation of 
both residues in the (-)VASP cells was observed (Figs. 6.1D and 6.1E).  Finally, when 
treated with AICAR the (-)VASP cells exhibited no change in phosphorylation status at 
either Ser157 or Thr278 compared to controls and, notably, significantly less 
phosphorylation compared to AICAR treatments alone (Figs. 6.1D and 6.1E).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 
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Figure 6.1. AMPK specifically phosphorylates VASP.  Cells were treated with AICAR (1 mM, 60 min) 
and VASP phosphorylation was analyzed by immunofluorescence with flow cytometry.  (A) AICAR 
significantly increases phosphorylation of VASP at Ser157 and Thr 278.  (B) Representative photograph 
of an ECL-based Western blot performed on A7R5 VSMC homogenates that reveals successful 
transduction of Lv-shRNA directed against full length VASP after incubation for 24 hours.  Lanes 
correspond to untreated control, vehicle control (Veh), non-targeting (scrambled) Lv-shRNA control 
(NTC), and three replicates of anti-VASP-Lv-shRNA-treated cells ((-)VASP).  (C) Graphical representation 
of results obtained from InCell Western blotting on intact adherent A7R5 VSMCs after 48 hours 
incubation with vehicle (Veh), NTC, or anti-VASP-Lv-shRNA ((-)VASP).  No changes were observed with 
Veh or NTC compared to controls (Cont); however, three replicates of VASP-deficient cells reveal 
significant and consistent knockout of VASP protein.  (D) and (E) Specificity of AICAR-induced 
phosphorylation of VASP Ser157 and VASP Thr278, respectively, in non-transduced and VASP-deficient 
A7R5 VSMCs.  VASP knockdown in cells reveal significantly less site-specific phosphorylation compared 
to controls and no differences were found following treatment with AICAR suggesting specificity of AMPK-
induced phosphorylation of these residues.  Data are presented as pVASP/total VASP, n=3-5 per group.  
P values less than 0.05 were considered statistically significant.  *= p<0.05 compared to control; **= 
p<0.005 compared to control; ***= p<0.001 compared to control; ∆ = p<0.05 compared to AICAR alone. 
 
VASP inhibition increases G:F-actin 
VASP acts as an anti-capping protein associated with polymerizing actin filaments; 
therefore, it is logical that increased inhibitory phosphorylation of VASP by AMPK would 
increase the cytoplasmic G-actin pool.  We have previously shown that AICAR-induced 
AMPK increases cytoplasmic G-actin in primary VSMCs (100), and data presented here 
show that AICAR stimulation significantly increases G:F-actin in commercial A7R5 
VSMCs (Fig. 6.2).  Additionally, as expected, VASP-deficient cells displayed even 
greater G:F-actin ratios and no significant differences were observed when VASP-
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deficient cells were treated with AICAR (Fig. 6.2), suggesting AMPK-specific inhibition 
of VASP leading to increased G:F-actin. 
 
Figure 6.2 
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Figure 6.2.  AMPK/VASP promotes actin de-polymerization.  Non-transduced and VASP-deficient 
VSMCs were treated with or without AICAR (1 mM, 60 min), fixed and stained for F-actin (fluorescently-
tagged phalloidin) or G-actin (fluorescently-tagged deoxyribonuclease I), and fluorescence was read by 
flow cytometry.  Immunofluorescence reveals that AICAR promotes F-actin disassembly as shown by 
increased G:F actin ratios.  VASP deficiency further increased G:F-actin, yet no differences were 
detected when VASP-deficient cells were treated with AICAR.  Data are presented as fold change of the 
total G-actin to F-actin fluorescence detected by flow cytometry for n=3-5 per group.  P values less than 
0.05 were considered statistically significant.  ** = p<0.005 compared to control; ***= p<0.001 compared 
to control; ∆ = p<0.05 compared to AICAR alone. 
 
VASP inhibition reduces actin strain on focal adhesions 
A proposed mechanism of focal adhesion kinase (FAK) autophosphorylation of 
Tyr397, an event necessary for kinase activation and focal adhesion turnover, is F-actin 
strain on the focal adhesion complex (26, 93, 107, 128).  It has been suggested that 
VASP may play a role in adhesion-directed actin polymerization (26, 129); therefore, the 
interaction of AMPK with VASP may subsequently reduce FAK auto-activation and 
warrants investigation.  We have previously reported AMPK-mediated inhibition of pFAK 
Tyr397; therefore, in light of the aforementioned data suggesting AMPK inhibition of 
VASP-mediated actin polymerization, we treated VASP-deficient cells with and without 
AICAR (1mM) and found that AICAR and VASP ablation each individually significantly 
reduced pFAK Tyr397 compared to control cells (Fig. 6.3).  Intriguingly, VASP-deficient 
cells treated with AICAR also showed significant reduction in pFAK Tyr397 (Fig. 6.3), 
yet to levels not significantly different than AICAR-treated or VASP-deficient cells alone 
suggesting these effects were indeed AMPK mediated. 
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Figure 6.3 
 
 
Figure 6.3.  AMPK/VASP inhibits FAK activation.  Non-transduced and VASP-deficient VSMCs were 
treated with or without AICAR (1 mM, 60 min) and FAK Tyr397 phosphorylation was measured  by flow 
cytometry as an indication of kinase activity.  AICAR treated cells revealed significant reduction in FAK 
activation.  Notably, VASP-deficient cells also revealed reduced FAK activity and no differences were 
observed when cells were simultaneously treated with AICAR.  Data are presented at pFAK Tyr397/total 
FAK detected by flow cytometry for 3-5 separate experiments.  P values less than 0.05 were considered 
statistically significant.  *** = p<0.001 compared to control. 
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The focal adhesion accessory protein paxillin is a marker of stable focal adhesions.  
Thus, in this study we treated non-transduced and VASP-deficient cells with AICAR and 
found significant increases in paxillin expression under both conditions (Fig. 6.4).  Once 
again, VASP-deficient cells treated with AICAR showed similar results yet were not 
significantly different than the other treatment group (Fig. 6.4) suggesting these results 
were AMPK specific. 
 
Figure 6.4 
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Figure 6.4.  AMPK/VASP promotes focal adhesion stability.  Non-transduced and VASP-deficient 
VSMCs were treated with or without AICAR (1 mM, 60 min) and paxillin expression was analyzed by 
immunolabeling and flow cytometry.  Protein analysis reveals that AMPK increases paxillin content, 
indicative of focal adhesion stability and anti-migratory signaling.  VASP-deficient VSMCs also showed 
significant elevation of paxillin expression.  Addition of AICAR to VASP-deficient cells revealed no 
significant differences from non-transduced cells suggesting VASP-dependence of AMPK on focal 
adhesion stability.  P values less than 0.05 were considered statistically significant for n=3-5 per group.  ** 
= p<0.005 compared to control; *** = p<0.001 compared to control. 
 
VASP knockdown inhibits VSMC migration 
If VASP inhibition reduces actin polymerization and subsequent actin strain on focal 
adhesions, then it would make sense that VASP inhibition, either by phosphorylation or 
genetic knockdown, should result in functional inhibition of VSMC migration.  We have 
previously shown AMPK-mediated inhibition of rat primary VSMCs (100, 101), and in 
the current study we demonstrate that AICAR significantly inhibits migration of rat A7R5 
VSMCs after 18 hours (Fig. 6.5).  As expected, migration was also inhibited with VASP 
deficiency which was not significantly different than AICAR alone or when VASP-/- cells 
were treated with AICAR (Fig. 6.5), providing further evidence for a functional 
relationship between AMPK and VASP. 
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Figure 6.5 
 
 
Figure 6.5.  AMPK/VASP inhibits VSMC migration.  Non-transduced and VASP-deficient VSMCs were 
labeled with CellTracker Green and treated with AICAR (1 mM), and PDGF-stimulated (10ng/mL) 
chemotaxis was evaluated using a modified Boyden chamber apparatus and bottom-read fluorescence at 
525 nm between 0 and 18 hours.  AICAR significantly reduced cell migration in non-transduced cells at 
18 hours.  VASP-deficient VSMCs also showed a significant reduction in migration; however, there were 
no significant differences between VASP-deficient with or without AICAR.  Two-way ANOVA with Tukey’s 
post-hoc testing was used for multiple comparisons across time and within each treatment group.  P 
values less than 0.05 across time within each group were considered statistically significant for n=3.  *** = 
p<0.001 compared to control. 
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VASP knockdown promotes VSMC cytostasis 
It has been suggested that VASP serves as a necessary mediator of Rho-induced 
serum response element transcriptional activity (129); therefore, we tested the effects of 
VASP ablation on VSMC proliferation.  In non-transduced A7R5 cells, AICAR reduced 
cells entering the G2/M phase of the cell cycle which corresponds to significant 
increases in cells found in the G0/G1 and S phases (Fig. 6.6).  Intriguingly, VASP 
deficiency completely reversed this AMPK-mediated cytostatic effect (Fig. 6.6) 
supporting the notion that VASP is necessary for entry into the cell cycle and provide 
novel insight to the functional role of AMPK-mediated VASP inhibition.  
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Figure 6.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6.  AMPK inhibits cell cycle progression in a VASP-dependent manner.  Non-transduced 
and VASP-deficient VSMCs were treated with or without AICAR (1 mM) for 24 hours following overnight 
quiescence.  Cell cycle progression was analyzed by flow cytometry using Draq5.  AICAR significantly 
inhibited cell cycle progression revealed by insignificant increases in G0/G1 phase cells, significant 
increases in S-phase cells, and significant reduction in G2/M cells.  VASP deficiency inhibited the 
cytostatic effect of AMPK revealed by complete reversal of the observed increase in S-phase cells and 
reduction in G2/M phase cells.  P values less than 0.05 were considered statistically significant after 
multiple comparisons and two-way ANOVA for n=3 experiments.  *** = p<0.001 compared to control; ∆ = 
p<0.05 compared to AICAR alone. 
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Discussion 
 
Findings presented in this study support our hypothesis that AMPK inhibits VSMC 
growth in VASP-dependent manner.  We have previously shown in rat primary VSMCs 
(101), and herein confirm in rat A7R5 VSMCs that AMPK has th ability to increase 
phosphorylation of VASP at both Ser157 and Thr278.  AMPK also possess anti-
migratory and anti-proliferative properties in VSMCs which we and others have 
previously documented (43, 67, 98, 100).  Given the role VASP as a conductor of cell 
signaling and regulator of cytoskeletal arrangement (4, 6, 7, 10, 15, 31, 91, 123, 129), in 
this study we investigated the dependence of AMPK on VASP to inhibit migration and 
proliferation of A7R5 VSMCs with an emphasis on focal adhesion biology.  Utilizing Lv-
shRNA targeted against full-length VASP, we successfully knocked down VASP as 
documented by Western blotting on cell homogenates and ICW blotting on intact 
adherent cells.  In turn, VASP deficiency resulted in reduction in f-actin polymerization, 
focal adhesion kinase activation and focal adhesion turnover as well as in cell migration 
and cell cycle progression.  Moreover, after treatment with AICAR to activate AMPK, the 
cytostatic functions of AMPK observed in control non-transduced cells was completely 
reversed with VASP knockdown.  Data presented here provide evidence for a novel 
signaling network in VASP through which AMPK inhibits VSMC growth and further 
support its role as a biologically active signaling protein within VSM capable of 
modulating deleterious VSM growth.   
The actin cytoskeleton acts as an anchoring point for focal adhesion and cell 
attachment; therefore, with decreased actin polymerization less force will be exerted on 
focal adhesions and in turn, directed filament elongation required for lamellipodia and 
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filopodia formation will be minimized.  Additionally, turnover of focal adhesions requires 
catalytic phosphorylation of FAK at Tyr397.  One suggested mechanism of FAK 
activation is by auto-phosphorylation following actin strain (26, 107, 128).  Therefore, in 
this study we sought to investigate the functional role of the AMPK/VASP relationship 
on actin dynamics and focal adhesion stability in light of VSM growth.  We have 
previously reported in rat primary VSMCs that AMPK has ability to increase 
phosphorylation of VASP at Ser157 and Thr278 either directly or via crosstalk with 
protein kinase A (101).  In similar fashion, in this study AICAR significantly increased 
pVASP Ser157 and Thr278 in A7R5 VSMCs (Fig. 6.1).  As VASP acts in a pro-
polymerization manner, when VASP gets phosphorylated by AMPK the G-actin pool 
should increase.  Figure 6.2 reveals that with AICAR treatment to stimulate AMPK, G-
actin is significantly increased compared to controls suggesting an inhibitory action of 
AMPK on VASP.  Catalytic phosphorylation of FAK was also significantly reduced after 
treatment with AICAR (Fig. 6.3) suggesting a functional link between inhibition of VASP-
mediated filament elongation and focal adhesion turnover.  Furthermore, Figure 6.4 
reveals that AMPK increased expression of the focal adhesion protein paxillin, which 
indicates a more stable focal adhesion complex.  Altogether, these data reveal a 
discrete signaling network between AMPK and VASP that leads to an inhibition of actin 
filament elongation and focal adhesion turnover.  Finally, as a functional readout of this 
biochemical relationship, VSMCs were exposed to PDGF-mediated chemotaxis in a 
transwell migration assay and results show that with AMPK stimulation, migration was 
reduced nearly fourfold after 18 hours compared to vehicle controls (Fig. 6.5). 
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To investigate the dependence of AMPK on VASP in its inhibition of VSMC growth 
we utilized Lv-shRNA against full length VASP and successfully knocked the protein 
down nearly ~80 percent as documented through ECL-based Western blotting on 
cellular homogenates and ICW blotting on intact cells (Figs. 6.1 B and 6.1C).  Again, 
testing the specificity of AMPK-mediated phosphorylation of VASP Ser157 and VASP 
Thr278, we analyzed VASP-deficient cells treated with and without AICAR and found no 
differences among the groups, thus suggesting AMPK dependence (Figs. 6.1 D and 
6.1E).  As expected, G-actin was even further increased with under conditions of VASP 
knockdown yet no difference was detected when VASP-deficient cells were treated with 
AICAR.  Additionally, pFAK Tyr397 was reduced significantly and paxillin was increased 
significantly in in VASP-deficient cells, yet with both pFAK and paxillin no differences 
were found between VASP-deficient cells treated with or without AICAR.  Finally, when 
VASP-deficient cells were exposed to PDGF stimulation and transwell chemotaxis, 
significant reduction in VSMC migration was observed in VASP mutants with no 
significant difference observed with or without AICAR.  Together these data suggest 
that the observed AMPK-mediated reduction in VSMC migration is indeed VASP-
dependent and operates through inhibitory phosphorylation of VASP leading to reduced 
microfilament elongation and strain on focal complexes. 
In this study we also tested the dependence of AMPK on VASP in its ability to inhibit 
VSM cell cycle progression.  We have previously reported that AMPK has capacity to 
inhibit VSM cell cycle progression and cell proliferation in primary VSMCs (100, 101) 
and herein we report similar findings.  In A7R5 VSMCs, AICAR was sufficient to 
significantly reduce cell cycle progression as illustrated by ~60% reduction in cells in the 
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G2/M phase of the cell cycle and significant increase in cells in the S phase with 
moderate increase in cells found in the G0/G1 phase.  Intriguingly, when we treated 
VASP-deficient cells with AICAR we found a complete reversal of the cytostatic effects 
of AMPK seen in non-transduced cells (Fig. 6.6).  While it remains unclear the exact 
mechanism of this VASP-dependent inhibition of cell cycle progression, it has been 
suggested that VASP is necessary for Rho-dependent serum response element (Sre) 
transcriptional activity (31, 129).  Additionally, it has been suggested that AMPK exhibits 
inhibitory crosstalk with RhoA in VSMCs (27).  Given this insight and the new evidence 
presented here that AMPK plays a regulatory role on VASP, we can confidently 
speculate that AMPK inhibits VSMC proliferation via inhibitory regulation of VASP and 
VASP-dependent Sre transcriptional activity; however, further investigation into this 
exact mechanism is needed.  Altogether, these data suggest that AMPK-mediated 
VSMC cytostasis is dependent upon VASP inhibition. 
Figure 6.7 depicts the suggested central role of VASP on AMPK-mediated control of 
VSMC proliferation and migration in A7R5 VSMCs based on these findings.  Through 
phosphorylation, AMPK exerts inhibitory control on VASP which reduces directed 
microfilament elongation and relieves focal adhesion strain.  This reduction in focal 
adhesion strain results in a more stable focal adhesion complex by reducing 
autophosphorylation of FAK and subsequent phosphorylation of accessory focal 
adhesion proteins.  VASP knockdown-mediated reduction in microfilament elongation 
reduces lamellipodia and filopodia formation required for cell chemotaxis, and with a 
more stable focal adhesion complex, membrane detachment from the extracellular 
matrix required for cell movement is ameliorated.  Additionally, VASP ablation appears 
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to reverse the observed AMPK-mediated cytostatic effect on VSMCs.  While the exact 
mechanism of this novel interaction remain unclear, it is certain that AMPK operates via 
VASP regulation to inhibit cell cycle progression and cell proliferation.  Altogether, this 
discrete AMPK/VASP nexus provides an attractive target for the regulation of VSMC 
growth in an effort to curb the deleterious growth associated with VSM-dependent 
proliferative disorders. 
 
Figure 6.7 
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Figure 6.7. Schematic depicting the proposed functional relationship of AMPK and VASP in the 
inhibition of VSMC growth.  AMPK exhibits inhibitory control of VASP through phosphorylation which 
reduces directed microfilament elongation and relieves focal adhesion strain.  A reduction in focal 
adhesion strain results in reduced autophosphorylation of focal adhesion kinase (FAK) and subsequent 
activation of accessory focal adhesion proteins including the GTP-ase RhoA.  Increased stability of focal 
adhesions ultimately reduces membrane detachment from the extracellular matrix which is required for 
cell movement.  Additionally, VASP inhibition reduces microfilament elongation necessary for lamellipodia 
and filopodia formation also required for cell movement.  Finally, VASP inhibition appears to reverse the 
observed AMPK-mediated cytostatic effect on VSMCs.  While the exact mechanism remains unclear, it is 
certain that AMPK operates to inhibit cell cycle progression and cell proliferation via regulation of VASP.   
 
	  
Chapter 7: Unified Discussion 
 
Key findings from this research project support our global hypothesis that AMPK has 
capacity to reduce arterial remodeling via inhibition of VSMC proliferation and migration.  
Ample data provide convincing evidence that AMPK operates by provoking cell cycle 
arrest and preventing cytoskeletal/focal adhesion restructuring necessary for VSMC 
migration.  These findings offer unique insight into AMPK signaling as a novel system 
with significant therapeutic potential in the remediation of vascular growth disorders.  
Smooth muscle-mediated vascular remodeling plays a pivotal role in the onset and 
complication of vasculoproliferative diseases (44, 62, 77); therefore, targeted therapies 
are of great clinical importance.  Data presented here lend strong support for AMPK as 
a biologically active signaling molecule within VSM capable of curbing cell migration and 
proliferation, key players in pathologic vessel remodeling. 
Using the well-established balloon injury model to induce VSMC-mediated vessel 
remodeling (109, 114, 116), we have illustrated that both systemic and local activation 
of AMPK is sufficient to markedly reducing neointimal formation (Figs. 3.1, 3.2).  In an 
effort to confirm the results observed by treatment with AICAR, we also utilized a 
specific and non-metabolic agonist of AMPK, the small molecule A-769662.  This agent 
has been documented to directly activate AMPK in cell-free systems, in intact cells, and 
in vivo without the side effects associated with the more traditional AMPK-activating 
biguanides (30).  Importantly, A-769662 has been recently characterized for use in 
activating AMPK in vascular cells (73).  In this study the results obtained from localized 
treatment of injured vessels with A-769662 paralleled the results obtained with use of 
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AICAR, thus confirming that the in vivo results as well as those obtained in vitro are 
attributed to AMPK and not off-target drug-specific effects.  Results using localized, 
perivascular delivery of AICAR or A-769662 are noteworthy and represent the first 
report demonstrating that local delivery of AMPK agonists immediately following 
intervention are biologically effective.  Often, an a priori treatment to reduce vessel 
remodeling is not possible and systemic therapies can suffer from undesired side 
effects; however, localized delivery of an agent at the time of vascular intervention 
capable of reducing iatrogenic complications offers high clinical translation. 
In order to examine underlying mechanisms of growth suppression by AMPK, in rat 
primary VSMCs following verification of the biologic activity of AICAR (Fig. 3.3) we show 
its ability to significantly reduce cell numbers through inhibition of cell cycle progression 
(Fig. 3.4, 4.9, 5.2, 6.6).  Flow cytometry revealed that AICAR exerts cytostasis in the 
G0/G1 and S phases with concomitant reduction in progression through to the G2/M 
phase.  Of note, no changes in cell viability were observed in any treatment group; 
therefore, the observed changes in cell number are likely due directly to alterations in 
cell cycle progression and not from overt cytotoxicity.  Additionally, these cytostatic 
effects were further supported by significant reductions in cell numbers analyzed by 
automated cell counting after 48 hours AICAR treatment (Figs. 3.4, 4.9, 5.3).  
It was previously suggested that AMPK has ability to promote cytostasis by cyclin-
dependent kinase inhibition via a p53/p21 pathway in a commercialized human VSM 
cell line (43); however, in addition to these findings, alternate mechanisms by which 
AMPK inhibits cell cycle progression are plausible.  Here we demonstrate that AMPK 
may operate through the G0/G1 cell cycle regulatory proteins cyclin D/CDK4/6, cyclin 
 
	    126	  
E/CDK2, and p21 and p27 to promote VSMC cytostasis.  Early G0/G1-dependent cyclin 
D and late G0/G1-dependent cyclin E were both significantly elevated by TGFβ; 
however, concomitant treatment with AICAR significantly reduced both cyclin D and 
cyclin E compared to control and cytokine-induced conditions (Fig. 5.4).  Both cyclin D-
associated CDK4 as well as cyclin E-associated CDK2 were significantly elevated by 
TGFβ but were completely reversed to below basal levels with concomitant AICAR (Fig. 
5.5).  Intriguingly, no change was observed in cyclin D-associated CDK6, possibly 
suggesting that TGFβ promotes cell cycle progression in a cyclin D/CDK4- then cyclin 
E/CDK2-specific fashion.   Furthermore, AICAR elevated both CDK inhibitors p21 and 
p27; however, only p21 remained elevated following co-treatment with TGFβ (Fig. 5.6).  
Taken together, these data suggest that AMPK has ability to inhibit TGFβ-induced cell 
cycle progression via reduction in G0/G1 cyclin D/CDK4 and cyclin E/CDK2 complexes 
through p21-mediated CDK inhibition.  
It has been reported that PP-2A has the ability to disrupt the cdc/cyclin B complex 
and inhibit G2/M progression.  Although traditional cell cycle inhibition occurs primarily in 
the G0/G1 phase, our cell cycle analysis revealed a large increase in S-phase cells; 
therefore, we investigated the hypothesis that PP-2A contributes to the mechanism for 
AMPK inhibition of VSMC proliferation.  Our data reveal that AMPK specifically induces 
PP-2A activity (Fig. 4.5A) and concomitantly reduces cdc2/cyclinB expression after 24 
hours (Fig. 4.5B) in nuclear fractions.  It is possible that in a pathologic state, as with our 
stimulated VSMCs, cell cycle regulation may occur at various points outside of G0/G1 as 
we observed.  Therefore, we suggest that AMPK has ability to induce S-phase 
cytostasis through increased PP-2A activity.   
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Finally, using rat A7R5 VSMCs, AICAR was sufficient to significantly reduce cell 
cycle progression as illustrated by ~60% reduction in cells in the G2/M phase of the cell 
cycle, a significant increase in cells in the S phase, and moderate increases in cells in 
the G0/G1 phase.  Intriguingly, when we treated Lv-shRNA-mediated VASP-deficient 
cells with AICAR we found a complete reversal of the cytostatic effects of AMPK seen in 
non-transduced cells (Fig. 6.6).  While the exact mechanism remains uncertain, it has 
been suggested that VASP is necessary for Rho-dependent serum response element 
(Sre) transcriptional activity and subsequent cell cylce progression (31, 129).  
Additionally, it has been suggested that AMPK exhibits inhibitory crosstalk with RhoA in 
VSMCs (27).  Given this new insight and the evidence presented here that AMPK plays 
a regulatory role on VASP, we can speculate that AMPK inhibits VSMC proliferation via 
inhibitory regulation of VASP and VASP-dependent transcriptional activity; however, 
further investigation is needed to confirm these early results.   
 In addition to proliferation, VSMC migration is important in the pathophysiology of 
vessel remodeling.  The physical movement of cells across a substrate is a complex 
process highly dependent upon the actin cytoskeleton and its interface with focal 
contacts and the extracellular matrix.  In this study we demonstrate that AMPK plays a 
key role in the inhibition of VSMC migration after 18 hours revealed by significant 
reduction in chemotaxis analyzed by PDGF-stimulated transwell migration (Figs. 3.6, 
4.8, 6.5).  We present here one of the first reports demonstrating that AMPK acts to 
inhibit VSMC migration, which could offer significant therapeutic insight for the curbing 
of multiple disease processes that arise from an induction of cell migration.   
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 Next we sought to explore specific mechanism employed by AMPK to inhibit VSMC 
migration and found discrete mechanisms suggesting AMPK regulates cytoskeletal and 
focal adhesion dynamics necessary to promote VSMC migration.  Actin polymerization 
and leading edge formation are critical for directional cellular movement; however, 
AMPK impairs actin polymerization, presumably by inhibiting the anti-capping potential 
of VASP through direct, site-specific phosphorylation (9).  The actin cytoskeleton-
associated protein VASP is implicated in the directionality of extra- to intra-cellular 
signaling events and regulation of focal adhesions, and, via nucleotide exchange factor 
regulation, helps control transcriptional activation (10, 31, 123, 129).   Site-specific 
VASP phosphorylation has also been used as readout of protein kinase signaling as we 
have recently reported (2, 47, 100, 101).  Here we observed significant enhancement of 
pVASP at T157 and the AMPK-specific T278 site by AICAR (Figs. 3.7, 4.3, 6.1).  The 
resulting impairment of actin polymerization is evidenced by concomitant accumulation 
of G-actin in the cytosol and increased stress fiber formation in cultured VSMCs (Figs. 
3.8, 6.2).  This reduction in F-actin was completely reversed with VASP deletion and no 
difference was detected with concomitant AICAR treatment (Fig. 6.2).  Together, these 
data argue that AMPK mechanistically hinders actin cytoskeletal rearrangement 
providing migration and growth retardation in a VASP-dependent manner. 
Unique findings presented here also reveal that AMPK has potential to inhibit focal 
adhesion turnover necessary for the movement of cells across or through substrata.  
We show that AICAR treatment impairs FAK activation by inhibiting Tyr397 
phosphorylation (Fig. 3.9 and 6.3), a necessary event for kinase activity (107).  Upon 
activation, FAK induces paxillin phosphorylation and targets GTPase activity at the focal 
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adhesion allowing for focal contact release (107).  Therefore, inhibition of FAK activity 
offers another possible mechanism by which AMPK mediates inhibition of migration.  
Additionally, it has been suggested that paxillin acts as a bi-directional membrane-to-
nucleus signaling molecule and that differential accumulation of paxillin in each cellular 
compartment is indicative of either a pro- or anti-synthetic/migratory event (38, 122).  
Our data reveal that AICAR prevents cytosolic accumulation of paxillin while promoting 
membrane stability (Fig. 3.10 and 6.4).  Additionally, pFAK Tyr397 was reduced and 
paxillin was significantly increased in VASP-deficient cells, yet with both pFAK and 
paxillin no differences were found in VASP-deficient cells treated with AICAR.  Taken 
together, these data reveal a potential anti-migratory signaling network via AMPK-
mediated inhibition of FAK and focal adhesion dissociation, potentially in a VASP-
dependent manner, thereby reducing pro-migratory signals and promoting focal 
adhesion stability and growth suppression. 
To more comprehensively address the biophysics of migrating and synthetic 
VSMCs, we assessed activity of the extracellular matrix (ECM)-degrading gelatinolytic 
MMPs.  Upon activation, VSMCs produce and secrete MMP-2 and MMP-9 that act to 
degrade the ECM and that allow for VSMC expansion/migration and collagen deposition 
(11, 46, 68).  Here we show that AICAR selectively impairs MMP-9 activity (Fig. 3.11), 
which we suggest promotes a more stable focal adhesion via reduced extracellular 
matrix degradation thus increasing focal adhesion/substratum connectivity.  Combined, 
these data suggest a novel role for AMPK in the reduction of MMP-9 activity that may 
play a key role in the inhibition of cellular migration via enhanced focal adhesion 
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contacts as well as matrix-based morphological changes in the vessel wall following 
injury.  
The scope of this project was quite extensive; however, there are potential 
limitations to this work, which include the absence of a transgenic model in our in vivo 
studies and knockdown of specific focal adhesion proteins downstream of our proposed 
AMPK/VASP nexus.  Additionally, further insight into the exact mechanism employed by 
VASP to promote cell proliferation is needed since our data clearly indicates a reversal 
of AMPK-mediated cell senescence with VASP knockdown.  With these limitations in 
mind, we have established collaboration with Dr. Nair Sreejayan at The University of 
Wyoming who has agreed to provide AMPKα2 kinase dead (AMPKα2-KD) mice for our 
in vivo studies and to provide primary cells from the knockouts for our in vitro studies.  
We plan to use these animals to provide further evidence of isoform specific growth 
inhibition by AMPK in VSMCs.  Additionally, since viral-mediated knockdown of proteins 
in vitro has been established in our lab, we plan to make further use of this technique to 
knockdown proteins integral to the AMPK/VASP growth inhibition nexus.  Similar work 
has already begun as we have established collaboration with Dr. Jeff Brault at East 
Carolina University to provide Smad3 viral constructs in an effort to establish this as the 
primary TGFβ-induced growth-promoting pathway inhibited by AMPK in cultured 
VSMCs.  With these methods established, we hope to have the data from chapters 4 
and 5 of this dissertation completed in the near future which will provide two additional 
manuscripts as well as a more complete picture of mechanisms employed by AMPK 
within VSMCs for growth inhibition.   
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In conclusion, convincing data presented here provide strong evidence that AMPK is 
a desirable anti-growth target in VSM.  Using the AMPK mimetic AICAR or the AMPK-
activating small molecule A-769662, we present in vivo and in vitro data supporting our 
claims that AMPK abrogates neointimal formation and reduces VSMC proliferation and 
migration.  Mechanistically, ample evidence suggests that AMPK acts to promote VSMC 
cytostasis via G0/G1 and S-phase inhibition and subsequent VSMC proliferation and 
through cell migration inhibition.  Specific mechanisms of AMPK-mediated cytostasis 
include the inhibition of growth-promoting signals and cell cycle regulatory cyclin/cdk 
proteins as well as VASP inhibition and microfilament/focal adhesion stability and 
reduced extracellular matrix turnover.  Intriguing early data from Chapter 6 suggest that 
the anti-migratory signals employed by AMPK, namely VASP and focal adhesions, may 
also play a central role in AMPK-mediated anti-proliferation.  All cytoskeletal 
rearrangements tested that are necessary for cell migration were ablated by AMPK, yet 
were reversed when VASP was knocked down.  Additionally, the functional inhibition of 
cell migration and proliferation by AMPK were also reversed with VASP deficiency.  
Together these early findings suggest that AMPK has capacity to inhibit VSMC growth 
through attenuation of migration and proliferation and that these events are at least in 
part dependent on it’s interaction with the microfilament and focal adhesion proteins.  
Thus, these data paint a comprehensive picture of discrete AMPK-mediated cytostatic 
signaling networks (Fig. 7.1) that have significant clinical relevance and could potentially 
be manipulated in efforts to reduce vasculoproliferative pathologies. 
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Figure 7.1 
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Figure 7.1. Schematic of proposed signaling network for AMPK-mediated cytostasis in VSMCs.  
Collectively, our data suggest AMPK plays a key role in regulating both intra- and extra-cellular events 
involved in VSMC proliferation and migration.  Vasodilator-stimulated phosphoprotein (VASP) is an actin 
polymerization protein which leads to directed microfilament elongation.  Given its connection with focal 
adhesions (FA), increased actin strain by microfilament elongation provides the physical stress necessary 
for focal adhesion kinase (FAK) activation via autophosphorylation at Tyr397.  Upon activation, FAK 
phosphorylates other FA proteins and recruits RhoA GTPases necessary for FA disassembly.  This FA 
turnover and simulatenous microfilament push on the cell membrane allows for directed cell migration.  
Here we illustrate that AMPK has ability to inhibit FAK activation and RhoA recruitment to FA complexes.  
Additionally, we show increased FA stability as indicated by increased membranous paxillin expression, a 
marker of stable FAs.  We suggest that the observed reduction in FAK activation with AICAR is due to 
reduced actin strain via inhibition of VASP.  These data illustrate that VASP inhibition results in reduced 
F-actin assembly.  Together, these data suggest that VASP inhibition reduces FA actin strain and 
subsequent FA turnover necessary to produce cell migration and are illustrated by sequence 1. 
Treatment of VSMCs with AICAR revealed significant reduction of matrix metalloproteinase-9 (MMP9) 
activity in conditioned media as well as a significant increase in tissue inhibitor of metalloproteinase-1 
(TIMP-1), an inhibitor of MMP-2 and MMP-9.  During vessel remodeling or cell migration, extracellular 
matrix proteins are continually broken down by MMPs and then re-synthesized in the extracellular space.  
Sequence 2 illustrates our proposed mechanism of AMPK activation of TIMP-1 and subsequent TIMP-1 
inhibition of MMP-9.  This mechanism of AMPK-mediated extracellular matrix stability could be utilized in 
vivo following injury to inhibit vessel remodeling and fibrosis, and in vitro by inhibiting VSMC migration. 
The exact role of transforming growth factor-β (TGFβ) signaling in VSMCs remains elusive.  Some 
reports suggest TGFβ signaling promotes cytostasis, while more recent reports suggest it promotes cell 
cycle progression.  We analyzed the effect of recombinant human TGFβ treatment on VSMCs by 
analyzing the expression profile of the TGFβ-mediated Smad signaling pathway and growth promoting 
cyclin/cdk complexes.  Sequence 3 illustrates how activated TGFβ receptors promote the phosphorylation 
of Smad2 and Smad3, which can then oligomerize with cytosolic Smad4 for nuclear translocation.  Upon 
activation of Smad 2 and 3 we found increased cyclin D/cdk 4 and cyclin E/cdk 2, both G0/G1 promoting 
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complexes.  However, with AICAR, both Smad3 and the cyclin/cdk complexes were significantly reduced 
with concomitant increase in inhibitory Smad7 and cell cycle inhibitor p21 (Sequence 4).  Together 
AICAR-mediated inhibition of TGFβ/Smad and cell cycle signaling as well as a significant reduction in 
TGFβ-mediated cell cycle progression and clonal cell expansion (data not shown), these data suggest 
that TGFβ increases VSMC growth and that AMPK has capacity to reduce these growth promoting 
signals. 
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